Antares Pharma (ATRS) 10-K 3 Mar 20 2019 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Feb. 28, 2020	Jun. 30, 2019
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Trading Symbol	ATRS
Entity Registrant Name	ANTARES PHARMA, INC.
Entity Central Index Key	0001016169
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		165,560,401
Entity Public Float			$ 527.9
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock, par value $0.01 per share
Security Exchange Name	NASDAQ
Entity File Number	1-32302
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	41-1350192
Entity Address, Address Line One	100 Princeton South
Entity Address, Address Line Two	Suite 300
Entity Address, City or Town	Ewing
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08628
City Area Code	609
Local Phone Number	359-3020
Document Annual Report	true
Document Transition Report	false
Documents Incorporated by Reference	DOCUMENTS INCORPORATED BY REFERENCE Portions of the definitive proxy statement for the registrant’s 2020 annual meeting of stockholders to be filed within 120 days after the end of the period covered by this annual report on Form 10-K are incorporated by reference into Part III of this annual report on Form 10-K.

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Current Assets:
Cash and cash equivalents	$ 23,201,000	$ 27,892,000
Short-term investments	22,520,000	0
Accounts receivable	35,074,000	18,976,000
Inventories	16,000,000	11,350,000
Contract assets	8,235,000	10,442,000
Prepaid expenses and other current assets	3,416,000	2,648,000
Total current assets	108,446,000	71,308,000
Equipment, molds, furniture and fixtures, net	15,961,000	14,895,000
Operating lease right-of-use assets	5,463,000
Intangibles, net	478,000	831,000
Goodwill	1,095,000	1,095,000
Other assets	1,308,000	148,000
Total Assets	132,751,000	88,277,000
Current Liabilities:
Accounts payable	12,905,000	11,135,000
Accrued expenses and other liabilities	16,523,000	11,997,000
Long-term debt, current portion		3,043,000
Operating lease liabilities, current portion	1,249,000
Deferred revenue	1,738,000	1,018,000
Total current liabilities	32,415,000	27,193,000
Long-term debt	40,395,000	22,083,000
Operating lease liabilities, long-term	5,441,000
Total liabilities	78,251,000	49,276,000
Commitments and contingencies (Note 12)
Stockholders’ Equity:
Preferred Stock: $0.01 par, authorized 3,000 shares, none outstanding
Common Stock: $0.01 par; authorized 300,000 shares; 165,221 and 159,721 issued and outstanding at December 31, 2019 and 2018, respectively	1,652,000	1,597,000
Additional paid-in capital	332,377,000	314,907,000
Accumulated deficit	(278,827,000)	(276,800,000)
Accumulated other comprehensive loss	(702,000)	(703,000)
Total Stockholders' Equity	54,500,000	39,001,000
Total Liabilities and Stockholders’ Equity	$ 132,751,000	$ 88,277,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2019	Dec. 31, 2018
Statement Of Financial Position [Abstract]
Preferred Stock, par value	$ 0.01	$ 0.01
Preferred Stock, shares authorized	3,000,000	3,000,000
Preferred Stock, shares outstanding	0	0
Common Stock, par value	$ 0.01	$ 0.01
Common Stock, shares authorized	300,000,000	300,000,000
Common Stock, shares issued	165,221,000	159,721,000
Common Stock, shares outstanding	165,221,000	159,721,000

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Revenue:
Total revenue	$ 123,864	$ 63,554	$ 54,515
Cost of revenue:
Total cost of revenue	50,475	31,065	27,466
Gross profit	73,389	32,489	27,049
Operating expenses:
Research and development	10,624	12,328	11,854
Selling, general and administrative	61,773	36,762	31,646
Total operating expenses	72,397	49,090	43,500
Gain on sale of assets		12,500	860
Operating income (loss)	992	(4,101)	(15,591)
Other income (expense):
Interest expense	(3,549)	(2,675)	(1,423)
Other, net	530	261	271
Total other expense, net	(3,019)	(2,414)	(1,152)
Net loss before income taxes	(2,027)	(6,515)	(16,743)
Net loss	$ (2,027)	$ (6,515)	$ (16,743)
Basic and diluted net loss per common share	$ (0.01)	$ (0.04)	$ (0.11)
Basic and diluted weighted average common shares outstanding	162,574	157,407	156,054
Product sales [Member]
Revenue:
Total revenue	$ 92,103	$ 47,870	$ 41,695
Cost of revenue:
Total cost of revenue	46,267	29,094	22,317
Licensing and Development Revenue [Member]
Revenue:
Total revenue	7,529	6,753	11,171
Royalties [Member]
Revenue:
Total revenue	24,232	8,931	1,649
Cost of development revenue [Member]
Cost of revenue:
Total cost of revenue	$ 4,208	$ 1,971	$ 5,149

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (2,027)	$ (6,515)	$ (16,743)
Foreign currency translation adjustment	1	(3)	15
Comprehensive loss	$ (2,026)	$ (6,518)	$ (16,728)

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]
Balance at Dec. 31, 2016	$ 45,218	$ 1,552	$ 297,826	$ (253,445)	$ (715)
Balance, shares at Dec. 31, 2016		155,168,000
Common stock issued under equity compensation plan, net of shares withheld for taxes	(249)	$ 2	(251)
Common stock issued under equity compensation plan, net of shares withheld for taxes, shares		196,000
Exercise of options	1,816	$ 13	1,803
Exercise of options, shares		1,311,000
Share-based compensation	3,490		3,490
Net loss	(16,743)			(16,743)
Cumulative effect of change in accounting principle			97	(97)
Other comprehensive income (loss)	15				15
Balance at Dec. 31, 2017	33,547	$ 1,567	302,965	(270,285)	(700)
Balance, shares at Dec. 31, 2017		156,675,000
Issuance of common stock	7,114	$ 21	7,093
Issuance of common stock, shares		2,137,000
Common stock issued under equity compensation plan, net of shares withheld for taxes	(543)	$ 5	(548)
Common stock issued under equity compensation plan, net of shares withheld for taxes, shares		462,000
Exercise of options	474	$ 4	470
Exercise of options, shares		447,000
Share-based compensation	4,927		4,927
Net loss	(6,515)			(6,515)
Other comprehensive income (loss)	(3)				(3)
Balance at Dec. 31, 2018	39,001	$ 1,597	314,907	(276,800)	(703)
Balance, shares at Dec. 31, 2018		159,721,000
Issuance of common stock	7,781	$ 23	7,758
Issuance of common stock, shares		2,307,000
Common stock issued under equity compensation plan, net of shares withheld for taxes	(1,131)	$ 7	(1,138)
Common stock issued under equity compensation plan, net of shares withheld for taxes, shares		664,000
Exercise of options	4,405	$ 25	4,380
Exercise of options, shares		2,529,000
Share-based compensation	6,470		6,470
Net loss	(2,027)			(2,027)
Other comprehensive income (loss)	1				1
Balance at Dec. 31, 2019	$ 54,500	$ 1,652	$ 332,377	$ (278,827)	$ (702)
Balance, shares at Dec. 31, 2019		165,221,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Cash flows from operating activities:
Net loss	$ (2,027,000)	$ (6,515,000)	$ (16,743,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation expense	6,470,000	4,927,000	3,490,000
Depreciation and amortization	2,557,000	2,724,000	2,104,000
Accretion of interest expense	322,000	210,000	119,000
Increase in inventory reserve	325,000	592,000	356,000
Gain on sale of assets		(12,500,000)	(860,000)
Other	95,000	51,000	68,000
Changes in operating assets and liabilities:
Accounts receivable	(16,095,000)	(7,099,000)	(2,798,000)
Inventories	(4,975,000)	(2,667,000)	(4,304,000)
Contract assets	(2,793,000)	(4,937,000)	1,268,000
Prepaid expenses and other current assets	(655,000)	(324,000)	(942,000)
Other assets	(371,000)		(94,000)
Accounts payable	926,000	5,164,000	(1,522,000)
Accrued expenses and other liabilities	4,888,000	5,029,000	1,122,000
Deferred revenue	718,000	(1,977,000)	(4,358,000)
Net cash used in operating activities	(10,615,000)	(17,322,000)	(23,094,000)
Cash flows from investing activities:
Proceeds from sale of assets	5,000,000	7,500,000	1,901,000
Purchases of equipment, molds, furniture and fixtures	(2,350,000)	(854,000)	(1,167,000)
Purchases of investment securities	(22,645,000)		(9,964,000)
Proceeds from maturities of investment securities		5,000,000	5,000,000
Additions to patent rights		(40,000)	(101,000)
Net cash provided by (used in) investing activities	(19,995,000)	11,606,000	(4,331,000)
Cash flows from financing activities:
Proceeds from issuance of long-term debt	15,000,000		25,000,000
Payment of debt issuance costs	(136,000)		(294,000)
Proceeds from issuance of common stock, net	7,781,000	7,114,000	0
Proceeds from exercise of stock options	4,405,000	474,000	1,816,000
Taxes paid related to net share settlement of equity awards	(1,131,000)	(543,000)	(249,000)
Net cash provided by financing activities	25,919,000	7,045,000	26,273,000
Effect of exchange rate changes on cash		1,000	(1,000)
Net increase (decrease) in cash and cash equivalents	(4,691,000)	1,330,000	(1,153,000)
Cash and cash equivalents:
Beginning of year	27,892,000	26,562,000	27,715,000
End of year	23,201,000	27,892,000	26,562,000
Supplemental disclosure of cash flow information:
Cash paid for interest	3,025,000	2,353,000	1,080,000
Supplemental disclosure of non-cash investing activities:
Gain on sales of assets recognized in excess of cash received		5,000,000
Purchases of equipment, molds, furniture and fixtures recorded in accounts payable and accrued expenses	$ 970,000	$ 49,000	40,000
Additions to patent rights recorded in accounts payable and accrued expenses			$ 10,000

Description of Business

Description of Business	12 Months Ended
	Dec. 31, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Description of Business	1. Description of Business Antares Pharma, Inc. (“Antares,” “we,” “our,” “us” or the “Company”) is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. We develop, manufacture and commercialize, for ourselves or with partners, novel therapeutic products using advanced drug delivery technology to enhance existing drug compounds and delivery methods. Our injection technology platforms include the VIBEX ® ® ® The Company markets and sells its proprietary product XYOSTED ® ® The Company also markets and sells its proprietary product OTREXUP ® Through its commercialization partner Teva, the Company sells Sumatriptan Injection USP, indicated in the U.S. for the acute treatment of migraine and cluster headache in adults. In collaboration with AMAG, the Company developed a subcutaneous auto injector for use with AMAG’s progestin hormone drug Makena ® ® Through a license, development and supply agreement with Teva, Antares developed and is the exclusive supplier of the device for Teva’s Epinephrine Injection USP, which is indicated for emergency treatment of severe allergic reactions in adults and certain pediatric patients. The product was approved by the FDA in August 2018 and launched for commercial sale in late fourth quarter of 2018. The Company is also developing two multi-dose pen injector products in collaboration with Teva, a combination drug device rescue pen in collaboration with Pfizer, a combination drug device product with Idorsia, and has other ongoing internal research and development programs.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The accompanying consolidated financial statements include the accounts of Antares Pharma, Inc. and its two wholly-owned foreign subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company’s most significant accounting estimates relate to revenue recognition, inventory valuation, and the valuation of equity instruments used in stock-based compensation. Actual results could differ from these estimates. Accounting Pronouncements Recently Adopted The Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) No. 2016-02 Leases (“Topic 842”) On January 1, 2018, the Company adopted ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) Revenue Recognition Recent Accounting Pronouncements Not Yet Adopted as December 31, 2019 In 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instruments However, in October 2019, the FASB issued ASU 2019-10, Financial Instruments - Credit Losses, Derivatives and Hedging, and Leases: Effective Dates . In 2018, the FASB issued ASU 2018-15, Intangibles – Goodwill and Other – Internal-Use Software: Accounting for Implementation Costs Incurred in Cloud Computing Arrangement that is a Service Contract, In 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and 606 Foreign Currency Translation The majority of the foreign subsidiaries’ revenues are denominated in U.S. dollars, and any required funding of the subsidiaries is provided by the U.S. parent. Nearly all operating expenses of the foreign subsidiaries are denominated in Swiss Francs. Additionally, bank accounts held by foreign subsidiaries are denominated in Swiss Francs, there is a low volume of intercompany transactions and there is not an extensive interrelationship between the operations of the subsidiaries and the parent company. As such, the Company has determined that the Swiss Franc is the functional currency for its foreign subsidiaries. The reporting currency for the Company is the United States Dollar (“USD”). The financial statements of the Company’s foreign subsidiaries are translated into USD for consolidation purposes. All assets and liabilities are translated using period-end exchange rates and statements of operations items are translated using average exchange rates for the period. The resulting translation adjustments are recorded as a separate component of stockholders’ equity, comprising all of the accumulated other comprehensive income (loss). Sales to certain customers and purchases from certain vendors by the U.S. parent are in currencies other than the USD and are subject to foreign currency exchange rate fluctuations. Foreign currency transaction gains and losses are included in other income (expense) in the consolidated statements of operations. Cash and Cash Equivalents Cash and cash equivalents consist of demand deposits at commercial banks and highly liquid investments in money market funds with maturities of three months or less. Cash equivalents are remeasured and reported at fair value each reporting period, in accordance with ASC Topic 820, Fair Value Measurements (“ASC 820”) three-level valuation hierarchy for disclosure of fair value measurements, and totaled $11,153 and $20,569 as of December 31, 2019 and 2018, respectively Investments From time to time, the Company also invests in U.S. Treasury bills and government agency notes that are classified as held-to-maturity because of the Company’s intent and ability to hold the securities to maturity. Investments with maturities of one year or less are classified as short-term. The investment securities are carried at their amortized cost and fair value is determined by quoted market prices for identical or similar securities. At December 31, 2019, the Company’s short-term investments had a carrying value of $22,520, which approximated fair value. The Company held no investments as of December 31, 2018. Accounts Receivable Trade accounts receivable represents amounts billed to customers and are stated at the amount the Company expects to collect. The Company considers the following factors when determining the collectability of specific customer accounts: customer creditworthiness, past transaction history with the customer and changes in customer payment terms. At December 31, 2019, the Company’s trade accounts receivable balance was due primarily from Teva, AMAG and distributors. Each of these customers has historically paid timely and demonstrated creditworthiness. Accordingly, the Company believes the risk of accounts being uncollectible is minimal and had no significant allowances for doubtful accounts established as of December 31, 2019 or 2018. If the financial condition of the Company’s customers were to deteriorate, adversely affecting their ability to make payments, additional allowances may be required. The Company had no material write-offs to bad debt expense in 2019, 2018 or 2017. Royalties receivable from partners are included in accounts receivable and are typically payable to the Company within 45 to 60 days after the end of each quarter and or annual period in which they were earned. Inventories Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. Certain components of the Company’s products are provided by a limited number of vendors, and the Company’s production and assembly operations are outsourced to third-party suppliers where substantially all of the Company’s inventory is located. Disruption of supply from key vendors or third-party suppliers may have a material adverse impact on the Company’s operations. Inventory consisted of the following: December 31, December 31, 2019 2018 Raw material $ 325 $ 26 Work in process 8,390 7,622 Finished goods 7,285 3,702 $ 16,000 $ 11,350 The Company provides reserves for potentially excess, dated or obsolete inventories based on estimates of forecasted product demand and the likelihood of consumption in the normal course of business, considering the expiration dates of the inventories on hand, planned production volumes and lead times required for restocking of customer inventories. Although every effort is made to ensure that forecasts and assessments are reasonable, changes to these assumptions are possible. In such cases, estimates may prove inaccurate and result in an understatement or overstatement of the reserves required to fairly state such inventories. The Company’s reserve for excess, dated or obsolete inventory was $464 and $847 at December 31, 2019 and 2018, respectively. In 2019, the Company wrote off inventory of $708 and increased the reserve for excess, dated or obsolete inventory by $325. In 2018, the Company wrote off $255 of inventory and increased the reserve for excess, dated or obsolete inventory by $592. Contract Assets Contract assets are recognized when control of goods or services has transferred to the customer, and corresponding revenue is recognized on an over time basis but is not yet billable to the customer in accordance with the terms of the contract. Costs that have been incurred in connection with development services provided to partners for which the associated revenue has not yet been recognized are also recorded as contract assets, and totaled $1,534 and $204 as of December 31, 2019 and 2018, respectively. As of December 31, 2018, contract assets also included a $5,000 installment in connection with the sale and transfer of assets to Ferring as discussed in Note 9, which was received during the year ended December 31, 2019. Equipment, Molds, Furniture, and Fixtures Equipment, molds, furniture, and fixtures are stated at cost and are depreciated using the straight-line method over their estimated useful lives ranging from three to ten years. The Company’s equipment, molds, furniture and fixtures consisted of the following: December 31, December 31, 2019 2018 Furniture, fixtures and office equipment $ 2,480 $ 2,331 Production molds and equipment 20,749 19,678 Molds and tooling in process 1,512 456 Construction in process 989 — Less: accumulated depreciation (9,769 ) (7,570 ) $ 15,961 $ 14,895 Depreciation expense was $2,205, $2,125 and $1,536 for the years ended December 31, 2019, 2018 and 2017, respectively. Leases The Company recognizes right-of-use (“ROU”) assets and lease liabilities when it obtains the right to control an asset under a leasing arrangement with an initial term greater than twelve months. The Company evaluates the nature of each lease at the inception of an arrangement to determine whether it is an operating or financing lease and recognizes the right-of-use asset and lease liabilities based on the present value of future minimum lease payments over the expected lease term. The Company’s leases do not generally contain an implicit interest rate and therefore the Company uses the incremental borrowing rate it would expect to pay to borrow on a similar collateralized basis over a similar term in order to determine the present value of its lease payments. Certain of the Company’s lease arrangements contain renewal options that have not been included in the determination of the lease term, as they are not reasonably certain of exercise. For contracts that contain lease and non-lease components, the Company accounts for both components as a single lease component. Variable lease payments are expensed as incurred. Intangible assets The Company capitalizes external legal costs and filing fees associated with obtaining patent rights for approved commercial and partnered products when there are projected future cash flows associated with the patent. These capitalized patent costs are amortized on a straight-line basis over the shorter of the life of the patent or the estimated useful life of the patent, which typically ranges from five to fifteen years beginning on the earlier of the date the patent is issued or the first commercial sale of product utilizing such patent rights. The Company periodically reviews capitalized patent costs to identify any amounts to be charged to expense for patents that are no longer being pursued or for which there are no future revenues or cash flows anticipated. The Company capitalizes external legal patent defense costs and costs for pursuing patent infringements when it determines that a successful outcome is probable and will lead to an increase in the value of the patent. The capitalized costs are amortized over the remaining life of the related patent. If changes in the anticipated outcome were to occur that reduce the likelihood of a successful outcome of the entire action to less than probable, the capitalized costs would be charged to expense in the period in which the change is determined. The gross carrying amount and accumulated amortization of patents was $3,661 and $3,183, respectively at December 31, 2019, and $3,794 and $2,963, respectively, at December 31, 2018. Patent amortization expense for the years ended December 31, 2019, 2018 and 2017 was $352, $599 and $568, respectively, and is recorded in selling, general and administrative expenses in the consolidated statements of operations. The Company’s estimated aggregate patent amortization expense for the next five years is $95, $89, $83, $68 and $49 in 2020, 2021, 2022, 2023 and 2024, respectively. Impairment of Long-Lived Assets and Intangibles Long-lived assets and intangibles, including patent rights, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset or asset group. This analysis can be very subjective; however, the Company utilizes the expected future undiscounted cash flows from signed license and distribution agreements and other contracts with customers to substantiate the recoverability of its long-lived assets. If the sum of the undiscounted cash flows is less than the carrying value of the asset, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. Goodwill Goodwill is evaluated for impairment annually at December 31, or more frequently if an event occurs or circumstances change that indicate that the carrying value may not be recoverable. In performing the annual impairment test, the Company compares the fair value of the reporting unit to the carrying amount and would recognize an impairment charge to goodwill for the amount by which the carrying amount exceeds the reporting unit’s fair value. At December 31, 2019 and 2018, the Company had goodwill with a carrying value of $1,095, attributable to its single reporting unit. Based on the results of its evaluations, the Company determined that goodwill was not impaired, and no impairment losses were recognized in the years ended December 31, 2019, 2018, and 2017, respectively. Revenue Recognition The Company generates revenue from proprietary and partnered product sales, license and development activities and royalty arrangements. Revenue is recognized when or as the Company transfers control of the promised goods or services to its customers at the transaction price, which is the amount that reflects the consideration to which it expects to be entitled to in exchange for those goods or services. At inception of each contract, the Company identifies the goods and services that have been promised to the customer and each of those that represent a distinct performance obligation, determines the transaction price including any variable consideration, allocates the transaction price to the distinct performance obligations and determines whether control transfers to the customer at a point in time or over time. Variable consideration is included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company reassess its reserves for variable consideration at each reporting date and makes adjustments, if necessary, The Company has elected to recognize the cost for freight and shipping activities as fulfilment cost. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of underlying goods are transferred to the customer. The related shipping and freight charges incurred by the Company are included in cost of revenue. Proprietary Product Sales The Company sells its proprietary products OTREXUP ® ® The determination of certain of these reserves and sales allowances require management to make a number of judgements and estimates to reflect the Company’s best estimate of the transaction price and the amount of consideration to which it believes it is ultimately entitled to receive. The expected value is determined based on unit sales data, contractual terms with customers and third-party payers, historical and expected utilization rates, any new or anticipated changes in programs or regulations that would impact the amount of the actual rebates, customer purchasing patterns, product expiration dates and levels of inventory in the distribution channel. Reserves for prompt payment discounts are recorded as a reduction in accounts receivable. Reserves for returns, distributor fees, rebates and customer co-pay support programs are included within current liabilities in our consolidated balance sheets. Wholesaler Distribution Fees . Distribution fees are paid to certain wholesalers based on contractually determined rates and units purchased. S ince the fee paid to the customer is not for a distinct good or service, the consideration is recognized as a reduction of the transaction price of the goods delivered in accordance with ASC 606. The Company accrues the estimated fee due at the time of sale based on the contracted price and adjusts the accrual at each reporting period, if necessary, to reflect actual experience. Prompt Pay Discounts . The Company offers cash discounts to its customers, generally 2% of the sales price, as an incentive for prompt payment. Based on historical experience, customers take advantage of this discount and accordingly the Company accrues 100% of the cash discounts offered by reducing accounts receivable and recognizing the discount as a reduction of revenue in the same period the related sales are made. The accrual is reviewed at each reporting period and adjusted if actual experience differs from estimates. Chargebacks . The Company provides discounts primarily to authorized users of the Federal Supply Schedule (“FSS”) of the General Services Administration under an FSS contract negotiated by the Department of Veterans Affairs and various organizations under Medicaid contracts and regulations. These entities purchase products from the wholesale distributors at a discounted price, and the wholesale distributors then charge back to the Company the difference between the current wholesale acquisition cost and the price the entity paid for the product. The Company will estimate and accrue chargebacks based on estimated wholesaler inventory levels, current contract prices and historical chargeback activity. Chargebacks are recognized as a reduction of revenue in the same period the related revenue is recognized. Rebates . The Company participates in certain plan rebate programs, which provide discounted prescriptions to qualified insured patients. Under these rebate programs, the Company will pay a rebate to the third-party administrator of the program, generally two to three months after the quarter in which prescriptions subject to the rebate are filled. The Company estimates and accrues for these rebates based on current contract prices, historical and estimated future percentages of product sold to qualified patients. Rebates are recognized as a reduction of revenue in the same period the related revenue is recognized. Patient Discount Programs. The Company also offers discount cards, co-pay coupons and free trial programs to off-set the cost of prescriptions to patients. The Company estimates the total amount that will be redeemed or utilized based on historical redemption experience and on levels of inventory in the distribution and retail channels and recognizes the discount as a reduction of revenue in the same period the related revenue is recognized. Product Returns. Consistent with industry practice, the Company generally offers wholesalers and specialty distributors a limited right to return products, generally within six months prior to and 12 months following the product’s expiration date. The Company’s propriety products generally have expiration dates ranging from 24 to 33 months. Product returns are estimated and recorded at the time of sale based on historical return patterns. Actual returns are tracked by individual production lots and charged against reserves. Returns reserves may be adjusted, if necessary, if actual returns differ from historical estimates. Management also monitors and takes into consideration the amount of estimated product inventory in the distribution channel, product dating and any known or expected changes in the marketplace when establishing the estimated rate of returns. The following presents changes in reserves for product returns and sales allowances: Patient Wholesaler Prompt Rebates and Discount Distribution Payment Chargebacks Programs Returns Fees Discounts Balance at December 31, 2017 $ 1,315 $ 115 $ 245 $ 465 $ 84 Accruals and adjustments 9,586 2,429 1,628 3,519 742 Payments and other reserve reductions (8,207 ) (1,254 ) (720 ) (3,194 ) (610 ) Balance at December 31, 2018 2,694 1,290 1,153 790 216 Accruals and adjustments 15,383 6,716 2,520 6,393 1,491 Payments and other reserve reductions (11,769 ) (7,161 ) (3,303 ) (5,500 ) (1,387 ) Balance at December 31, 2019 $ 6,308 $ 845 $ 370 $ 1,683 $ 320 Partnered Product Sales The Company is party to several license, development, supply and distribution arrangements with pharmaceutical partners, under which the Company produces and is the exclusive supplier of certain products, devices and/or components. Revenue is recognized when or as control of the goods transfers to the customer as follows: The Company is the exclusive supplier of the Makena ® All other partnered product sales are recognized at the point in time in which control is transferred to the customer, which is typically upon shipment. Sales terms and pricing are governed by the respective supply and distribution agreements, and there is generally no price protection or right of return. Revenue is recognized at the transaction price, which includes the contractual per unit selling price and estimated variable consideration, if any. For example, the Company sells Sumatriptan Injection USP to Teva at cost and is entitled to receive 50 percent of the net profits from commercial sales made by Teva, payable to the Company within 45 days after the end of the quarter in which the commercial sales are made. The Company recognizes revenue, including the estimated variable consideration it expects to receive for contract margin on future commercial sales, upon shipment of the goods to Teva. The estimated variable consideration is recognized at an amount the Company believes is not subject to significant reversal based on historical experience, and is adjusted at each reporting period if the most likely amount of expected consideration changes or becomes fixed. Licensing and Development Revenue The Company has entered into several license, development and supply arrangements with pharmaceutical partners under which the Company grants a license to its device technology and know-how and provides research and development services that often involve multiple performance obligations and highly customized deliverables. For such arrangements, the Company identifies each of the promised goods and services within the contract and the distinct performance obligations at inception, and allocates consideration to each performance obligation based on relative standalone selling price, which is generally determined based on the expected cost plus margin. If the contract includes an enforceable right to payment for performance completed to date and performance obligations are satisfied over time, the Company recognized revenue over the development period using either the input or output method depending on which is most appropriate given the nature of the distinct deliverable. For other contracts that do not contain an enforceable right to payment for performance completed to date, revenue is recognized when control is transferred to the customer. Factors that may indicate that the transfer of control has occurred include the transfer of legal title, transfer of physical possession, the customer has obtained the significant risks and rewards of ownership of the assets and the Company has a present right to payment. The Company’s typical payment terms for development contracts may include an upfront payment equal to a percentage of the total contract value with the remaining portion to be billed upon completion and transfer of the individual deliverables or satisfaction of the individual performance obligations. The Company records a liability for cash received in advance of performance, which is presented within deferred revenue on the consolidated balance sheet and recognized as revenue when the associated performance obligations have been satisfied. License fees and milestones received in exchange for the grant of a license to the Company’s functional intellectual property (“IP”) such as patented technology and know-how in connection with a partnered development arrangement are generally recognized at inception of the arrangement, or over the development period depending on the facts and circumstances, as the license is not generally distinct from the non-licensed goods or services to be provided under the contract. Milestone payments that are contingent upon the occurrence of future events, are evaluated and recorded at the most likely amount, and to the extent that it is probable that a significant reversal will not occur when the associated uncertainty is resolved. Royalties The Company earns royalties in connection with licenses granted under license and development arrangements with partners. Royalties are based upon a percentage of commercial sales of partnered products with rates ranging from mid single digit to low double digit and are tiered based on levels of net sales. These sales-based royalties, for which the license was deemed the predominant element to which the royalties relate, are estimated and recognized in the period in which the partners’ commercial sales occur. The royalties are generally reported and payable to the Company within 45 to 60 days of the end of the period in which the commercial sales are made. The Company bases its estimates of royalties earned on actual sales information from its partners when available or estimated prescription sales from external sources and estimated net selling price. If actual royalties received are different than amounts estimated, the Company would adjust the royalty revenue in the period in which the adjustment becomes known. Remaining Performance Obligations Remaining performance obligations represents the transaction price of firm orders and development contract deliverables for which work has not been completed or orders fulfilled, and excludes potential purchase orders under ordering-type supply contracts with indefinite delivery or quantity. As of December 31, 2019, the aggregate value of remaining performance obligations, excluding contracts with an original expected length of one year or less, was $7.5 million. The Company expects to recognize revenue on the remaining performance obligations over the next three years, with the majority being recognized in the next twelve months. Share-Based Compensation The Company utilizes share-based compensation in the form of stock options, restricted stock units (“RSUs”) and performance-based restricted stock units (“PSUs”). The Company records compensation expense associated with share-based awards granted to employees at the fair value of the award on the date of grant. The Company uses the Black-Scholes option valuation model to determine the fair value of stock options. The fair values of RSU and PSU grants containing service or performance conditions are based on the market value of the Company’s Common Stock on the date of grant. The fair value of PSUs containing a market condition are estimated using a Monte Carlo simulation. The value of the portion of the award that is ultimately expected to vest is expensed ratably over the requisite service period as compensation expense in the consolidated statements of operations. Forfeitures are recorded as incurred. Assumptions concerning the Company’s stock price volatility and projected employee exercise behavior over the contractual life of the award impact the estimated fair value of the stock option awards. Research and Development Research and development expenses include costs directly attributable to the conduct of research and development programs including personnel costs, materials and supplies associated with design work and prototype development, FDA filing fees and the cost of services provided by outside contractors such as expenses related to clinical trials. All costs associated with research and development activities are expensed as incurred. Income Taxes Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Net Loss Per Share Basic net loss per share is computed by dividing net income or loss available to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed similar to basic net loss per share except that the weighted average shares outstanding are increased to include additional shares from the assumed exercise of stock options and warrants, if dilutive. The number of additional shares is calculated by assuming that outstanding stock options or warrants were exercised and that the proceeds from such exercise were used to acquire shares of common stock at the average market price during the reporting period. All potentially dilutive common shares were excluded from the calculation because they were anti-dilutive for all annual periods presented. Potentially dilutive securities excluded from dilutive loss per share were 17,103, 17,147 and 14,761 at December 31, 2019, 2018 and 2017, respectively. Segment Information Operating segments are components of an enterprise for which separate financial information is available and is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker currently evaluates the Company’s operations as a whole from a number of different operational perspectives, including but not limited to, on a product-by-product, customer and partner basis. The Company derives all significant revenues from self-administered parenteral pharmaceutical products and technologies, and has a single reportable operating segment of business. Going Concern Management is responsible for evaluating, and providing disclosure of uncertainties about, the Company’s ability to continue as a going concern. As of December 31, 2019, the Company had cash, cash equivalents and investments of $45,721. Based on management’s evaluation, management concluded there is no substantial doubt or uncertainty about the Company’s ability to meet its obligations within one year from the date the consolidated financial statements were issued.

Leases

Leases	12 Months Ended
	Dec. 31, 2019
Leases [Abstract]
Leases	3. Leases As of December 31, 2018, the Company had non-cancellable operating leases for its corporate headquarters facility in Ewing, New Jersey, and its office, research and development facility in Plymouth, Minnesota, a suburb of Minneapolis. In connection with the adoption of Topic 842 on January 1, 2019, the Company recognized approximately $1.0 million in right-of-use assets and lease liabilities. During the first quarter of 2019, the Company also entered into a master operating lease arrangement for a fleet of vehicles for use by its sales force. In May 2019, the Company amended its existing lease of the Company’s corporate headquarters to extend the lease term for an additional two years. The lease extension period commences on November 1, 2019 and expires on October 31, 2021. On July 1, 2019, the Company entered into a new operating lease for approximately 75,000 square feet of office, laboratory, manufacturing and warehousing space in Minnetonka, Minnesota. The initial lease term is 12.5 years and the Company may renew the lease, at its option, for one additional renewal period of three years. The landlord delivered possession of the premises to the Company on July 1, 2019 and payment of rent commenced on January 1, 2020. The lease provides for the payment of fixed base rent and additional rent for operating expenses, insurance premiums and taxes. The Company is performing the build-out of the premises at the Company’s cost with an allowance for tenant improvement to be reimbursed by the landlord up to $1.2 million. The leases require payment of all executory costs such as maintenance and property taxes. Operating lease costs were $1,391 for the year ended December 31, 2019. Cash paid for amounts included in the measurement of operating lease liabilities was $1,401 for the year ended December 31, 2019 and non-cash operating lease ROU assets obtained in exchange for operating lease obligations were $6,511. As of December 31, 2019, the weighted average discount rate was approximately 8.3% and the weighted average remaining lease term was 8.4 years. The following table summarizes the Company’s operating lease maturities as of December 31, 2019: 2020 $ 1,552 2021 1,436 2022 893 2023 638 2024 650 Thereafter 4,933 Total remaining lease payments 10,102 Less: Interest (3,412 ) Total lease liabilities $ 6,690 Under the prior leasing standard, future minimum lease payments under operating leases as of December 31, 2018 were as follows: 2019 $ 566 2020 233 2021 238 2022 60 Thereafter — Total future minimum lease payments $ 1,097 Rent expense for operating leases was $695 and $656 for the years ended December 31, 2018 and 2017, respectively.

Accrued Expenses and Other Liab

Accrued Expenses and Other Liabilities	12 Months Ended
	Dec. 31, 2019
Payables And Accruals [Abstract]
Accrued Expenses and Other Liabilities	4 . Accrued Expenses and Other Liabilities Accrued expenses and other liabilities consisted of the following: December 31, December 31, 2019 2018 Accrued employee compensation and benefits $ 4,479 $ 3,715 Product returns and sales allowances 9,206 5,927 Other liabilities 2,838 2,355 $ 16,523 $ 11,997

Long-Term Debt

Long-Term Debt	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Long-Term Debt	5 . Long-Term Debt On June 6, 2017, the Company entered into a loan and security agreement (the “Loan Agreement”) with Hercules Capital, Inc., for a term loan of up to $35.0 million (the “Term Loan”), under which the Company initially borrowed $25.0 million (“Tranche I”), the proceeds of which are being used for working capital and general corporate purposes. The Term Loan is secured by substantially all of the Company’s assets, excluding intellectual property, and will mature on July 1, 2022. Interest accrues at a calculated prime-based variable rate with a maximum interest rate of 9.50%. The interest rate in effect as of December 31, 2019 and 2018 was 9.25% and 9.5%, respectively. Payments under the Loan Agreement are interest only until the first principal payment is due, which was originally on August 1, 2019. O n June 26, 2019, the Company entered into a First Amendment (the “Amendment”) to the Loan Agreement, which increased the aggregate principal amount available under the Term Loan from $ 35.0 million to $ 50.0 million and extended the interest-only payment period of the Term Loan to August 1, 2021, which may be further extended to August 1, 2022 if the Company achieves a certain loan extension milestone. Upon signing of the Amendment, an additional $ 15.0 million (“Tranche II”) was funded to the Company. The Term Loan maturity date remained July 1, 2022, but may be extended to July 1, 2024 contingent upon satisfaction of a certain loan extension milestone . The Company may, but is not obligated to, request one or more additional advances of at least $ 5.0 million, not to exceed $ 10.0 million in the aggregate (“Tranche III”). The Company’s option to request additional advances is available between January 1, 2020 and September 15, 2020. The Company is required to pay an end of term fee (“End of Term Charge”) equal to 4.25% of Tranche I and 3.95% of the borrowings under Tranche II and Tranche III, payable upon the earlier of July 1, 2022 or repayment of the loan. The Loan Agreement also imposes a prepayment fee of 1.0% to 3.0% if any or all of the balance is prepaid prior to the maturity date As of December 31, 2019, and 2018, the carrying value of the Term Loan was $40,395 and $25,126, respectively, which consisted of the principal balance outstanding and the End of Term Charge accrual, less unamortized debt issuance costs that are being amortized/accrued to interest expense over the term of the Term Loan using the effective interest method. The fair value of the Company’s debt is estimated to approximate the carrying value based on management’s understanding of current market conditions and rates it could obtain for similar loans. Future principal payments under the Term Loan, including the contractual End of Term Charge, are as follows: 2020 $ — 2021 16,215 2022 25,440 $ 41,655

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2019
Equity [Abstract]
Stockholders' Equity	6 . Stockholders’ Equity In August 2017, the Company entered into a sales agreement (the “Sales Agreement”) with Cowen and Company, LLC (“Cowen”) under which the Company could offer and sell, from time to time and at its sole discretion, shares of its common stock having an aggregate offering price of up to $30.0 million through Cowen as the Company’s sales agent and/or as principal. Cowen could sell the common stock by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415 of the Securities Act of 1933, as amended (the “ATM Facility”.) The Sales Agreement required the Company to pay a commission of 3.0% of the gross sales proceeds of any common stock sold through Cowen. During year ended December 31, 2019, the Company sold 2,307 shares of common stock under the ATM Facility, resulting in net offering proceeds to the Company of $7,781. The Company issued 2,137 shares of common stock pursuant to the Offering and Sales Agreement during the year ended December 31, 2018 resulting in net offering proceeds to the Company of $7,114. No sales of common stock were made in the period ended December 31, 2017. On June 26, 2019, the Company delivered written notice to Cowen that it was terminating the Sales Agreement effective July 6, 2019, and accordingly the ATM Facility is no longer available for use.

Share Based Compensation

Share Based Compensation	12 Months Ended
	Dec. 31, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Share Based Compensation	7 . Share-Based Compensation The Company has an Equity Compensation Plan (the “Plan”), which was amended and restated pursuant to stockholder approval on June 13, 2019 in order to increase the number of shares available for issuance under the Plan by 8,000, extend the term of the Plan and modify certain provisions. The Plan allows for grants in the form of incentive stock options, nonqualified stock options, stock units, stock awards, stock appreciation rights, and other stock-based awards. All of the Company’s officers, directors, employees, consultants and advisors are eligible to receive grants under the Plan. The cumulative number of shares that have been authorized for issuance under the Plan to date is 40,200 and the maximum number of shares of stock that may be granted to any one participant during a calendar year is 4,000 shares. Options to purchase shares of common stock are granted at exercise prices not less than 100% of fair market value on the dates of grant. The term of each option is ten years and the options typically vest over a three-year Stock option exercises , and the vesting of restricted stock and performance stock awards, are satisfied through the issuance of new shares. Stock Options Stock option activity under the Plan as of and for the three years ended December 31, 2019 is as follows: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Shares Price ($) Term (Years) Value ($) Outstanding at December 31, 2016 11,314 1.84 Granted/Issued 2,986 2.67 Exercised (1,311 ) 1.38 2,226 Cancelled/Forfeited (840 ) 2.68 Outstanding at December 31, 2017 12,149 2.04 Granted/Issued 2,693 2.72 Exercised (477 ) 1.14 768 Cancelled/Forfeited (286 ) 2.43 Outstanding at December 31, 2018 14,079 2.19 6.8 8,534 Granted/Issued 2,489 3.01 Exercised (2,572 ) 1.76 6,477 Cancelled/Forfeited (135 ) 2.81 Outstanding at December 31, 2019 13,861 2.41 6.7 31,713 Exercisable at December 31, 2019 10,033 2.22 5.8 24,835 The per share weighted average fair value of options granted during 2019, 2018 and 2017 was estimated as $1.54, $1.45 and $1.37, respectively, on the date of grant using the Black-Scholes option pricing model based on the assumptions noted in the table below. Expected volatilities are based on the historical volatility of the Company’s stock. The weighted average expected life is based on both historical and anticipated employee behavior. December 31, 2019 2018 2017 Risk-free interest rate 1.9 % 2.8 % 1.8 % Annualized volatility 55.7 % 53.7 % 53.3 % Weighted average expected life, in years 5.5 6.0 6.0 Expected dividend yield 0.0 % 0.0 % 0.0 % Option exercises during 2019, 2018 and 2017 resulted in proceeds of $4,405, $474 and $1,816, respectively, and in the issuance of shares of common stock of 2,529 in 2019, 447 in 2018 and 1,311 in 2017. In 2019 and 2018, certain options were net exercised, whereby the Company withheld 43 and 30 shares, respectively, the fair value of which was equivalent to the aggregate exercise price and tax withholding on the date of exercise There were no net share exercises in 2017. Long Term Incentive Program The Company’s Board of Directors has approved a long-term incentive program (“LTIP”) for the benefit of the Company’s senior executives. Pursuant to the LTIP, the Company’s senior executives are awarded stock options, restricted stock units (“RSU”) and performance stock units (“PSU”) with targeted values based on similar award structures granted by the Company’s peer group. The stock options have a ten-year The performance stock unit awards and restricted stock unit awards granted under the long-term incentive program are summarized in the following table: Performance Stock Units Restricted Stock Units Number of Shares Weighted Average Date Fair Value ($) Number of Shares Weighted Average Grant Date Fair Value ($) Outstanding at December 31, 2016 1,347 1.50 823 1.39 Granted 689 3.12 689 2.69 Vested/settled — (288 ) 1.49 Forfeited/expired (581 ) 2.16 (67 ) 1.70 Outstanding at December 31, 2017 1,455 2.20 1,157 2.12 Granted 611 2.89 611 2.70 Vested/settled (173 ) 2.18 (500 ) 1.99 Forfeited/expired (51 ) 3.01 (42 ) 2.68 Outstanding at December 31, 2018 1,842 2.41 1,226 2.44 Granted 593 2.99 789 2.92 Incremental shares earned 59 1.25 — — Vested/settled (415 ) 1.18 (614 ) 2.19 Forfeited/expired (238 ) 1.12 — — Outstanding at December 31, 2019 1,841 3.00 1,401 2.82 The outstanding balance of PSU awards is stated at the target number of shares to be awarded upon attainment of certain performance goals. Depending on the outcome of the related performance goals, a recipient may ultimately earn a number of shares that is greater or less than the target number of units granted, ranging from 0% to 150%. The balance of PSU awards outstanding as of December 31, 2019 included 662 units granted in 2017 with a performance period ended December 31, 2019 that were subsequently deemed to be achieved and approved for settlement in the first quarter of 2020 for a total of 388 shares. In each of the years in the three-year period ended December 31, 2019, the LTIP awards include PSUs that will be earned based on the Company’s total shareholder return (“TSR”) as compared to the Nasdaq Biotechnology Index (“NBI”) at the end of the respective annual performance periods. The fair values of the TSR PSUs granted were determined using a Monte Carlo simulation and utilized the following inputs and assumptions: 2019 Award 2018 Award 2017 Award Closing stock price on grant date $ 2.92 $ 2.70 $ 2.66 Performance period starting price $ 3.01 $ 1.92 $ 2.17 Term of award (in years) 2.55 2.57 2.57 Volatility 63.7 % 64.9 % 54.6 % Risk-free interest rate 1.79 % 2.56 % 1.39 % Expected dividend yield 0.00 % 0.00 % 0.00 % Fair value per TSR PSU $ 3.18 $ 3.27 $ 3.10 The performance period starting price is measured as the average closing price over the last 20 trading days prior to the performance period start. The Monte Carlo simulation model also assumed correlations of returns of the prices of the Company’s common stock and the common stocks of the NBI companies and stock price volatilities of the NBI companies. The fair value of the target number of shares that can be earned under the TSR PSUs is being recognized as compensation expense over the term of the award. Other PSU awards that are not market-based awards are expensed using the grant date fair value of shares expected to vest over the remaining performance period when it becomes probable that the related performance goal will be achieved. LTIP awards are generally net-share settled such that the Company withholds shares with value equivalent to the employees’ minimum statutory obligation for the applicable income and other employment taxes, and remits cash to the appropriate taxing authorities. Total shares withheld for net-settled awards were 409, 211 and 98 in 2019, 2018 and 2017, respectively, and were based on the value of the shares on their vesting date as determined by the Company’s closing stock price. Total payments for the employees’ tax obligations to the taxing authorities were $1,131, $543 and $249 in 2019, 2018 and 2017, respectively, and are reflected as a financing activity within the consolidated statements of cash flows. These net-share settlements reduced the number of shares that would have otherwise been issued as a result of the vesting. Share-based Compensation Expense The Company incurred compensation costs in connection with share-based awards in each of the years in the three-year period ended December 31, 2019 as follows: December 31, 2019 2018 2017 Stock options $ 3,436 $ 2,956 $ 2,378 Restricted stock units 1,830 1,173 701 Performance stock units 1,204 798 411 Total share-based compensation expense $ 6,470 $ 4,927 $ 3,490 As of December 31, 2019, there was $4,780 of total unrecognized compensation costs related to non-vested stock option awards that are expected to be recognized over a weighted average period of approximately 1.9 years

Employee 401(k) Savings Plan

Employee 401(k) Savings Plan	12 Months Ended
	Dec. 31, 2019
Compensation And Retirement Disclosure [Abstract]
Employee 401(k) Savings Plan	8 . Employee 401(k) Savings Plan The Company sponsors a 401(k) defined contribution retirement savings plan that covers all U.S. employees who have met minimum age and service requirements. Under the plan, eligible employees may contribute a portion of their annual compensation into the plan up to the IRS annual limits. The Company has elected to make matching contributions to the plan based on a percentage of employee contributions.

Sale of Assets

Sale of Assets	12 Months Ended
	Dec. 31, 2019
Sale Of Assets [Abstract]
Sale of Assets	9. Sale of Assets In October 2017, the Company entered into an asset purchase agreement (the “Asset Purchase Agreement”) with Ferring International Center S.A. (together with Ferring Pharmaceuticals Inc. and Ferring B.V. individually and collectively referred to as “Ferring”) to sell the worldwide rights, including certain assets, related to the needle-free auto injector device product line for a total purchase price of $14.5 million. The purchase price was to be paid in four installments consisting of the following: a $2.0 million upfront payment, which was received upon entry into the Asset Purchase Agreement and the transfer of certain assets; a second installment of $2.75 million received upon delivery of certain documentation and satisfaction of certain conditions primarily related to product manufacturing; a third installment of $4.75 million received upon satisfaction of certain conditions, including further document transfer, the successful completion of a regulatory audit by a notified body, and a pilot manufacturing run under Ferring’s supervision; and a final installment of $5.0 million due upon Ferring’s receipt of the CE Mark needed to continue to commercialize the product in certain territories and the final transfer of certain product-related inventory, equipment and agreements to Ferring (the “Completion Date”). On May 1, 2019, the Company and Ferring entered into the First Amendment of the Asset Purchase Agreement (the “First Amendment”) to extend the term of the agreement to the third anniversary, to provide for the manufacture and delivery of additional product by Antares to Ferring prior to the Completion Date, and to bifurcate the payment of the final installment of the purchase price such that $2.5 million was paid to the Company upon the First Amendment effective date, with the final remaining payment of $2.5 million to be paid at the Completion Date, which was received in October 2019. The Company previously recorded the gain on sale of assets as it was determined that, based on the satisfaction of certain conditions and the status of remaining closing requirements, it was probable that a significant reversal of the gain would not occur. The final installments received w ere recorded as a reduction to the related contr act asset balance and a cash inflow from investing activities in the consolidated statement of cash flows for the year ended December 31, 2019 .

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Income Taxes	10. Income Taxes The Company was subject to taxes in both the U.S. and Switzerland in each of the years in the three-year 2019 2018 2017 U.S. $ (1,734 ) $ (6,696 ) $ (16,762 ) Switzerland (293 ) 181 19 $ (2,027 ) $ (6,515 ) $ (16,743 ) Effective tax rates differ from statutory income tax rates in the years ended December 31, 2019, 2018 and 2017 as follows: 2019 2018 2017 Statutory income tax rate (21.0 )% (21.0 )% (34.0 )% State income taxes (14.4 ) (3.8 ) (6.1 ) Valuation allowance increase 59.9 20.8 (102.0 ) Effect of foreign operations 1.0 (0.2 ) — Change in unused net operating loss and credit carryforwards (24.7 ) (3.9 ) 2.7 Stock-based compensation (22.3 ) (0.2 ) (3.5 ) 162(m) limitation 18.2 2.9 — Nondeductible items 1.8 3.2 (1.6 ) Impact of Tax Cuts and Jobs Act 1.5 2.2 144.5 0.0 % 0.0 % 0.0 % Deferred tax assets (liabilities) as of December 31, 2019 and 2018 consist of the following: 2019 2018 Gross deferred tax assets: Net operating loss carryforward – U.S. $ 41,780 $ 42,966 Net operating loss carryforward – Switzerland 52 7 Research and development tax credit carryforward 7,559 6,891 Deferred revenue — 105 Stock-based compensation 1,999 2,324 Inventory reserve 307 440 Compensation accruals 1,154 904 Product reserves 2,329 1,302 Operating lease liabilities 1,763 — 163j interest expense limitation 475 438 Amortization 585 562 Other 61 329 Total deferred tax assets 58,064 56,268 Deferred tax liabilities: Depreciation (1,807 ) (1,511 ) Right-of-use asset, operating leases (1,648 ) — Installment obligations — (1,363 ) Total deferred tax liabilities (3,455 ) (2,874 ) Net deferred tax asset before valuation allowance 54,609 53,394 Less valuation allowance (54,609 ) (53,394 ) Net deferred tax asset $ — $ — The valuation allowance for deferred tax assets as of December 31, 2019 and 2018 was $54,609 and $53,394, respectively. The total valuation allowance increased $1,215 for the year ended December 31, 2019 and increased $1,356 for the year ended December 31, 2018. At both December 31, 2019 and 2018, the Company had deferred tax assets, net of valuation allowances, of zero. In assessing the realizability of deferred tax assets, management considered whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences become deductible or in which net operating loss or tax credit carryforwards can be utilized. After considering both positive and negative evidence with respect to the U.S. deferred tax assets, management determined that as of December 31, 2019, it continues to be more likely than not that the U.S. deferred tax assets will not be realized and has recorded a valuation allowance against all U.S. deferred tax assets. The Company has a U.S. federal net operating loss carryforward at December 31, 2019 of $166,196, which, subject to limitations of Internal Revenue Code (“IRC”) Section 382, is available to reduce income taxes payable in future years. If not used, the portion of the carryforward generated before 2018 will expire in years 2020 through 2037, and the net operating loss carryforward generated in 2018, 2019 and any future years will carry forward indefinitely. Additionally, the Company has U.S. Research Credit carryforwards of $6,888. These credits expire in years 2020 through 2039. Utilization of U.S. net operating losses and tax credits of the Company may be subject to annual limitations under IRC Sections 382 and 383, respectively. The Company anticipates net operating losses will be utilized against current year U.S. taxable income. The annual limitations, for tax years other than 2019, if any, have not yet been determined. When a review is performed and if any annual limitations are determined, then the gross deferred tax assets for the net operating losses and tax credits would be reduced with a reduction in the valuation allowance of a like amount. The Company also has a Swiss net operating loss carryforward at December 31, 2019, of $365, which is available to reduce income taxes payable in future years. If not used, this carryforward will begin to expire in 2023. As of December 31, 2019 and 2018, there were no unrecognized tax benefits. Accordingly, a tabular reconciliation from beginning to ending periods is not provided. The Company will classify any future interest and penalties as a component of income tax expense if incurred. To date, there have been no interest or penalties charged or accrued in relation to unrecognized tax benefits. The Company does not anticipate that the total amount of unrecognized tax benefits will change significantly in the next twelve months. The Company is subject to federal and state examinations for the years 2013 and thereafter. There are no tax examinations currently in progress.

Revenues, Significant Customers

Revenues, Significant Customers and Concentrations of Risk	12 Months Ended
	Dec. 31, 2019
Revenue From Contract With Customer [Abstract]
Revenues, Significant Customers and Concentrations of Risk	11. Revenues, Significant Customers and Concentrations of Risk The following table presents the Company’s revenue on a disaggregated basis by major types and sources: For the Years Ended December 31, 2019 2018 2017 Proprietary product sales $ 39,215 $ 17,532 $ 17,946 Partnered product sales 52,888 30,338 23,749 Total product revenue 92,103 47,870 41,695 Licensing and development revenue 7,529 6,753 11,171 Royalties 24,232 8,931 1,649 Total revenue $ 123,864 $ 63,554 $ 54,515 Revenues disaggregated by customer geographic location are summarized as follows: For the Years Ended December 31, 2019 2018 2017 United States of America $ 120,231 $ 57,033 $ 48,924 Europe 3,463 6,157 5,061 Other 170 364 530 $ 123,864 $ 63,554 $ 54,515 Significant customers from which the Company derived 10% or more of its total revenue in any of the periods presented are as follows: For the Years Ended December 31, 2019 2018 2017 Teva 41% 31% 38% AMAG 20% 29% 16% AmerisourceBergen (1) 10% 11% 11% McKesson (1) <10% 12% 16% Ferring <10% 11% 10% (1) Revenue from sales to distributors, net of estimated sales returns and allowances based on shipments.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2019
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	12. Commitments and Contingencies From time to time, the Company may be involved in various legal matters generally incidental to its business. Although the results of litigation and claims cannot be predicted with certainty, after discussion with legal counsel, management is not aware of any matters for which the likelihood of a loss is probable and reasonably estimable and which could have a material impact on its consolidated financial condition, liquidity, or results of operations. On October 23, 2017, Randy Smith filed a complaint in the District of New Jersey, captioned Randy Smith, Individually and on Behalf of All Others Similarly Situated v. Antares Pharma, Inc., Robert F. Apple and Fred M. Powell Smith ® ® Smith On January 12, 2018, a stockholder of the Company filed a derivative civil action, captioned Chiru Mackert, derivatively on behalf of Antares Pharma, Inc., v. Robert F. Apple, et al. Vikram Rao, Derivatively on Behalf of Antares Pharma, Inc. v. Robert F. Apple, et al. Smith Smith On January 17, 2018, a stockholder of the Company filed a derivative civil action, captioned Robert Clark, Derivatively on Behalf of Antares Pharma, Inc. v. Robert F. Apple, et al. Clark Smith Clark Smith

Quarterly Financial Data (unaud

Quarterly Financial Data (unaudited)	12 Months Ended
	Dec. 31, 2019
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Data (unaudited)	13. Quarterly Financial Data (unaudited) First Second Third Fourth 2019 Total revenues $ 23,286 $ 28,433 $ 34,306 $ 37,839 Gross profit 12,340 15,992 21,244 23,813 Net income (loss) (5,539 ) (2,226 ) 1,043 4,695 Net income (loss) per common share (1) (0.03 ) (0.01 ) 0.01 0.03 Weighted average shares, basic 160,446 162,734 163,119 163,952 Weighted average shares, diluted 160,446 162,734 168,503 171,238 2018 Total revenues $ 12,703 $ 14,162 $ 17,868 $ 18,821 Gross profit 5,517 7,202 10,579 9,191 Net income (loss) (6,193 ) (4,520 ) (1,936 ) 6,134 Net income (loss) per common share (1) (0.04 ) (0.03 ) (0.01 ) 0.04 Weighted average shares, basic 156,724 157,024 157,471 158,389 Weighted average shares, diluted 156,724 157,024 157,471 162,810 (1) Net income (loss) per common share is computed based upon the net income or loss divided by the weighted average number of shares outstanding during each period. Basic and diluted weighted average shares and income (loss) per share amounts were identical for the periods in which the Company generated net losses, as the effect of potential common shares were anti-dilutive. For the periods in which the Company generated net income, the weighted average shares on a fully diluted basis, taking into consideration the effects of dilutive stock options, restricted stock and performance stock awards for the periods in which the Company generated net income, resulted in the income per share being mathematically the same on both a basic and diluted basis.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements include the accounts of Antares Pharma, Inc. and its two wholly-owned foreign subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company’s most significant accounting estimates relate to revenue recognition, inventory valuation, and the valuation of equity instruments used in stock-based compensation. Actual results could differ from these estimates.
Recent Accounting Pronouncements	Accounting Pronouncements Recently Adopted The Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) No. 2016-02 Leases (“Topic 842”) On January 1, 2018, the Company adopted ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) Revenue Recognition Recent Accounting Pronouncements Not Yet Adopted as December 31, 2019 In 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instruments However, in October 2019, the FASB issued ASU 2019-10, Financial Instruments - Credit Losses, Derivatives and Hedging, and Leases: Effective Dates . In 2018, the FASB issued ASU 2018-15, Intangibles – Goodwill and Other – Internal-Use Software: Accounting for Implementation Costs Incurred in Cloud Computing Arrangement that is a Service Contract, In 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and 606
Foreign Currency Translation	Foreign Currency Translation The majority of the foreign subsidiaries’ revenues are denominated in U.S. dollars, and any required funding of the subsidiaries is provided by the U.S. parent. Nearly all operating expenses of the foreign subsidiaries are denominated in Swiss Francs. Additionally, bank accounts held by foreign subsidiaries are denominated in Swiss Francs, there is a low volume of intercompany transactions and there is not an extensive interrelationship between the operations of the subsidiaries and the parent company. As such, the Company has determined that the Swiss Franc is the functional currency for its foreign subsidiaries. The reporting currency for the Company is the United States Dollar (“USD”). The financial statements of the Company’s foreign subsidiaries are translated into USD for consolidation purposes. All assets and liabilities are translated using period-end exchange rates and statements of operations items are translated using average exchange rates for the period. The resulting translation adjustments are recorded as a separate component of stockholders’ equity, comprising all of the accumulated other comprehensive income (loss). Sales to certain customers and purchases from certain vendors by the U.S. parent are in currencies other than the USD and are subject to foreign currency exchange rate fluctuations. Foreign currency transaction gains and losses are included in other income (expense) in the consolidated statements of operations.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents consist of demand deposits at commercial banks and highly liquid investments in money market funds with maturities of three months or less. Cash equivalents are remeasured and reported at fair value each reporting period, in accordance with ASC Topic 820, Fair Value Measurements (“ASC 820”) three-level valuation hierarchy for disclosure of fair value measurements, and totaled $11,153 and $20,569 as of December 31, 2019 and 2018, respectively
Investments	Investments From time to time, the Company also invests in U.S. Treasury bills and government agency notes that are classified as held-to-maturity because of the Company’s intent and ability to hold the securities to maturity. Investments with maturities of one year or less are classified as short-term. The investment securities are carried at their amortized cost and fair value is determined by quoted market prices for identical or similar securities. At December 31, 2019, the Company’s short-term investments had a carrying value of $22,520, which approximated fair value. The Company held no investments as of December 31, 2018.
Accounts Receivable	Accounts Receivable Trade accounts receivable represents amounts billed to customers and are stated at the amount the Company expects to collect. The Company considers the following factors when determining the collectability of specific customer accounts: customer creditworthiness, past transaction history with the customer and changes in customer payment terms. At December 31, 2019, the Company’s trade accounts receivable balance was due primarily from Teva, AMAG and distributors. Each of these customers has historically paid timely and demonstrated creditworthiness. Accordingly, the Company believes the risk of accounts being uncollectible is minimal and had no significant allowances for doubtful accounts established as of December 31, 2019 or 2018. If the financial condition of the Company’s customers were to deteriorate, adversely affecting their ability to make payments, additional allowances may be required. The Company had no material write-offs to bad debt expense in 2019, 2018 or 2017. Royalties receivable from partners are included in accounts receivable and are typically payable to the Company within 45 to 60 days after the end of each quarter and or annual period in which they were earned.
Inventories	Inventories Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. Certain components of the Company’s products are provided by a limited number of vendors, and the Company’s production and assembly operations are outsourced to third-party suppliers where substantially all of the Company’s inventory is located. Disruption of supply from key vendors or third-party suppliers may have a material adverse impact on the Company’s operations. Inventory consisted of the following: December 31, December 31, 2019 2018 Raw material $ 325 $ 26 Work in process 8,390 7,622 Finished goods 7,285 3,702 $ 16,000 $ 11,350 The Company provides reserves for potentially excess, dated or obsolete inventories based on estimates of forecasted product demand and the likelihood of consumption in the normal course of business, considering the expiration dates of the inventories on hand, planned production volumes and lead times required for restocking of customer inventories. Although every effort is made to ensure that forecasts and assessments are reasonable, changes to these assumptions are possible. In such cases, estimates may prove inaccurate and result in an understatement or overstatement of the reserves required to fairly state such inventories. The Company’s reserve for excess, dated or obsolete inventory was $464 and $847 at December 31, 2019 and 2018, respectively. In 2019, the Company wrote off inventory of $708 and increased the reserve for excess, dated or obsolete inventory by $325. In 2018, the Company wrote off $255 of inventory and increased the reserve for excess, dated or obsolete inventory by $592.
Contract Assets	Contract Assets Contract assets are recognized when control of goods or services has transferred to the customer, and corresponding revenue is recognized on an over time basis but is not yet billable to the customer in accordance with the terms of the contract. Costs that have been incurred in connection with development services provided to partners for which the associated revenue has not yet been recognized are also recorded as contract assets, and totaled $1,534 and $204 as of December 31, 2019 and 2018, respectively. As of December 31, 2018, contract assets also included a $5,000 installment in connection with the sale and transfer of assets to Ferring as discussed in Note 9, which was received during the year ended December 31, 2019.
Equipment, Molds, Furniture, and Fixtures	Equipment, Molds, Furniture, and Fixtures Equipment, molds, furniture, and fixtures are stated at cost and are depreciated using the straight-line method over their estimated useful lives ranging from three to ten years. The Company’s equipment, molds, furniture and fixtures consisted of the following: December 31, December 31, 2019 2018 Furniture, fixtures and office equipment $ 2,480 $ 2,331 Production molds and equipment 20,749 19,678 Molds and tooling in process 1,512 456 Construction in process 989 — Less: accumulated depreciation (9,769 ) (7,570 ) $ 15,961 $ 14,895 Depreciation expense was $2,205, $2,125 and $1,536 for the years ended December 31, 2019, 2018 and 2017, respectively.
Leases	Leases The Company recognizes right-of-use (“ROU”) assets and lease liabilities when it obtains the right to control an asset under a leasing arrangement with an initial term greater than twelve months. The Company evaluates the nature of each lease at the inception of an arrangement to determine whether it is an operating or financing lease and recognizes the right-of-use asset and lease liabilities based on the present value of future minimum lease payments over the expected lease term. The Company’s leases do not generally contain an implicit interest rate and therefore the Company uses the incremental borrowing rate it would expect to pay to borrow on a similar collateralized basis over a similar term in order to determine the present value of its lease payments. Certain of the Company’s lease arrangements contain renewal options that have not been included in the determination of the lease term, as they are not reasonably certain of exercise. For contracts that contain lease and non-lease components, the Company accounts for both components as a single lease component. Variable lease payments are expensed as incurred.
Intangible assets	Intangible assets The Company capitalizes external legal costs and filing fees associated with obtaining patent rights for approved commercial and partnered products when there are projected future cash flows associated with the patent. These capitalized patent costs are amortized on a straight-line basis over the shorter of the life of the patent or the estimated useful life of the patent, which typically ranges from five to fifteen years beginning on the earlier of the date the patent is issued or the first commercial sale of product utilizing such patent rights. The Company periodically reviews capitalized patent costs to identify any amounts to be charged to expense for patents that are no longer being pursued or for which there are no future revenues or cash flows anticipated. The Company capitalizes external legal patent defense costs and costs for pursuing patent infringements when it determines that a successful outcome is probable and will lead to an increase in the value of the patent. The capitalized costs are amortized over the remaining life of the related patent. If changes in the anticipated outcome were to occur that reduce the likelihood of a successful outcome of the entire action to less than probable, the capitalized costs would be charged to expense in the period in which the change is determined. The gross carrying amount and accumulated amortization of patents was $3,661 and $3,183, respectively at December 31, 2019, and $3,794 and $2,963, respectively, at December 31, 2018. Patent amortization expense for the years ended December 31, 2019, 2018 and 2017 was $352, $599 and $568, respectively, and is recorded in selling, general and administrative expenses in the consolidated statements of operations. The Company’s estimated aggregate patent amortization expense for the next five years is $95, $89, $83, $68 and $49 in 2020, 2021, 2022, 2023 and 2024, respectively.
Impairment of Long-Lived Assets and Intangibles	Impairment of Long-Lived Assets and Intangibles Long-lived assets and intangibles, including patent rights, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset or asset group. This analysis can be very subjective; however, the Company utilizes the expected future undiscounted cash flows from signed license and distribution agreements and other contracts with customers to substantiate the recoverability of its long-lived assets. If the sum of the undiscounted cash flows is less than the carrying value of the asset, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.
Goodwill	Goodwill Goodwill is evaluated for impairment annually at December 31, or more frequently if an event occurs or circumstances change that indicate that the carrying value may not be recoverable. In performing the annual impairment test, the Company compares the fair value of the reporting unit to the carrying amount and would recognize an impairment charge to goodwill for the amount by which the carrying amount exceeds the reporting unit’s fair value. At December 31, 2019 and 2018, the Company had goodwill with a carrying value of $1,095, attributable to its single reporting unit. Based on the results of its evaluations, the Company determined that goodwill was not impaired, and no impairment losses were recognized in the years ended December 31, 2019, 2018, and 2017, respectively.
Revenue Recognition	Revenue Recognition The Company generates revenue from proprietary and partnered product sales, license and development activities and royalty arrangements. Revenue is recognized when or as the Company transfers control of the promised goods or services to its customers at the transaction price, which is the amount that reflects the consideration to which it expects to be entitled to in exchange for those goods or services. At inception of each contract, the Company identifies the goods and services that have been promised to the customer and each of those that represent a distinct performance obligation, determines the transaction price including any variable consideration, allocates the transaction price to the distinct performance obligations and determines whether control transfers to the customer at a point in time or over time. Variable consideration is included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company reassess its reserves for variable consideration at each reporting date and makes adjustments, if necessary, The Company has elected to recognize the cost for freight and shipping activities as fulfilment cost. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of underlying goods are transferred to the customer. The related shipping and freight charges incurred by the Company are included in cost of revenue. Proprietary Product Sales The Company sells its proprietary products OTREXUP ® ® The determination of certain of these reserves and sales allowances require management to make a number of judgements and estimates to reflect the Company’s best estimate of the transaction price and the amount of consideration to which it believes it is ultimately entitled to receive. The expected value is determined based on unit sales data, contractual terms with customers and third-party payers, historical and expected utilization rates, any new or anticipated changes in programs or regulations that would impact the amount of the actual rebates, customer purchasing patterns, product expiration dates and levels of inventory in the distribution channel. Reserves for prompt payment discounts are recorded as a reduction in accounts receivable. Reserves for returns, distributor fees, rebates and customer co-pay support programs are included within current liabilities in our consolidated balance sheets. Wholesaler Distribution Fees . Distribution fees are paid to certain wholesalers based on contractually determined rates and units purchased. S ince the fee paid to the customer is not for a distinct good or service, the consideration is recognized as a reduction of the transaction price of the goods delivered in accordance with ASC 606. The Company accrues the estimated fee due at the time of sale based on the contracted price and adjusts the accrual at each reporting period, if necessary, to reflect actual experience. Prompt Pay Discounts . The Company offers cash discounts to its customers, generally 2% of the sales price, as an incentive for prompt payment. Based on historical experience, customers take advantage of this discount and accordingly the Company accrues 100% of the cash discounts offered by reducing accounts receivable and recognizing the discount as a reduction of revenue in the same period the related sales are made. The accrual is reviewed at each reporting period and adjusted if actual experience differs from estimates. Chargebacks . The Company provides discounts primarily to authorized users of the Federal Supply Schedule (“FSS”) of the General Services Administration under an FSS contract negotiated by the Department of Veterans Affairs and various organizations under Medicaid contracts and regulations. These entities purchase products from the wholesale distributors at a discounted price, and the wholesale distributors then charge back to the Company the difference between the current wholesale acquisition cost and the price the entity paid for the product. The Company will estimate and accrue chargebacks based on estimated wholesaler inventory levels, current contract prices and historical chargeback activity. Chargebacks are recognized as a reduction of revenue in the same period the related revenue is recognized. Rebates . The Company participates in certain plan rebate programs, which provide discounted prescriptions to qualified insured patients. Under these rebate programs, the Company will pay a rebate to the third-party administrator of the program, generally two to three months after the quarter in which prescriptions subject to the rebate are filled. The Company estimates and accrues for these rebates based on current contract prices, historical and estimated future percentages of product sold to qualified patients. Rebates are recognized as a reduction of revenue in the same period the related revenue is recognized. Patient Discount Programs. The Company also offers discount cards, co-pay coupons and free trial programs to off-set the cost of prescriptions to patients. The Company estimates the total amount that will be redeemed or utilized based on historical redemption experience and on levels of inventory in the distribution and retail channels and recognizes the discount as a reduction of revenue in the same period the related revenue is recognized. Product Returns. Consistent with industry practice, the Company generally offers wholesalers and specialty distributors a limited right to return products, generally within six months prior to and 12 months following the product’s expiration date. The Company’s propriety products generally have expiration dates ranging from 24 to 33 months. Product returns are estimated and recorded at the time of sale based on historical return patterns. Actual returns are tracked by individual production lots and charged against reserves. Returns reserves may be adjusted, if necessary, if actual returns differ from historical estimates. Management also monitors and takes into consideration the amount of estimated product inventory in the distribution channel, product dating and any known or expected changes in the marketplace when establishing the estimated rate of returns. The following presents changes in reserves for product returns and sales allowances: Patient Wholesaler Prompt Rebates and Discount Distribution Payment Chargebacks Programs Returns Fees Discounts Balance at December 31, 2017 $ 1,315 $ 115 $ 245 $ 465 $ 84 Accruals and adjustments 9,586 2,429 1,628 3,519 742 Payments and other reserve reductions (8,207 ) (1,254 ) (720 ) (3,194 ) (610 ) Balance at December 31, 2018 2,694 1,290 1,153 790 216 Accruals and adjustments 15,383 6,716 2,520 6,393 1,491 Payments and other reserve reductions (11,769 ) (7,161 ) (3,303 ) (5,500 ) (1,387 ) Balance at December 31, 2019 $ 6,308 $ 845 $ 370 $ 1,683 $ 320 Partnered Product Sales The Company is party to several license, development, supply and distribution arrangements with pharmaceutical partners, under which the Company produces and is the exclusive supplier of certain products, devices and/or components. Revenue is recognized when or as control of the goods transfers to the customer as follows: The Company is the exclusive supplier of the Makena ® All other partnered product sales are recognized at the point in time in which control is transferred to the customer, which is typically upon shipment. Sales terms and pricing are governed by the respective supply and distribution agreements, and there is generally no price protection or right of return. Revenue is recognized at the transaction price, which includes the contractual per unit selling price and estimated variable consideration, if any. For example, the Company sells Sumatriptan Injection USP to Teva at cost and is entitled to receive 50 percent of the net profits from commercial sales made by Teva, payable to the Company within 45 days after the end of the quarter in which the commercial sales are made. The Company recognizes revenue, including the estimated variable consideration it expects to receive for contract margin on future commercial sales, upon shipment of the goods to Teva. The estimated variable consideration is recognized at an amount the Company believes is not subject to significant reversal based on historical experience, and is adjusted at each reporting period if the most likely amount of expected consideration changes or becomes fixed. Licensing and Development Revenue The Company has entered into several license, development and supply arrangements with pharmaceutical partners under which the Company grants a license to its device technology and know-how and provides research and development services that often involve multiple performance obligations and highly customized deliverables. For such arrangements, the Company identifies each of the promised goods and services within the contract and the distinct performance obligations at inception, and allocates consideration to each performance obligation based on relative standalone selling price, which is generally determined based on the expected cost plus margin. If the contract includes an enforceable right to payment for performance completed to date and performance obligations are satisfied over time, the Company recognized revenue over the development period using either the input or output method depending on which is most appropriate given the nature of the distinct deliverable. For other contracts that do not contain an enforceable right to payment for performance completed to date, revenue is recognized when control is transferred to the customer. Factors that may indicate that the transfer of control has occurred include the transfer of legal title, transfer of physical possession, the customer has obtained the significant risks and rewards of ownership of the assets and the Company has a present right to payment. The Company’s typical payment terms for development contracts may include an upfront payment equal to a percentage of the total contract value with the remaining portion to be billed upon completion and transfer of the individual deliverables or satisfaction of the individual performance obligations. The Company records a liability for cash received in advance of performance, which is presented within deferred revenue on the consolidated balance sheet and recognized as revenue when the associated performance obligations have been satisfied. License fees and milestones received in exchange for the grant of a license to the Company’s functional intellectual property (“IP”) such as patented technology and know-how in connection with a partnered development arrangement are generally recognized at inception of the arrangement, or over the development period depending on the facts and circumstances, as the license is not generally distinct from the non-licensed goods or services to be provided under the contract. Milestone payments that are contingent upon the occurrence of future events, are evaluated and recorded at the most likely amount, and to the extent that it is probable that a significant reversal will not occur when the associated uncertainty is resolved. Royalties The Company earns royalties in connection with licenses granted under license and development arrangements with partners. Royalties are based upon a percentage of commercial sales of partnered products with rates ranging from mid single digit to low double digit and are tiered based on levels of net sales. These sales-based royalties, for which the license was deemed the predominant element to which the royalties relate, are estimated and recognized in the period in which the partners’ commercial sales occur. The royalties are generally reported and payable to the Company within 45 to 60 days of the end of the period in which the commercial sales are made. The Company bases its estimates of royalties earned on actual sales information from its partners when available or estimated prescription sales from external sources and estimated net selling price. If actual royalties received are different than amounts estimated, the Company would adjust the royalty revenue in the period in which the adjustment becomes known. Remaining Performance Obligations Remaining performance obligations represents the transaction price of firm orders and development contract deliverables for which work has not been completed or orders fulfilled, and excludes potential purchase orders under ordering-type supply contracts with indefinite delivery or quantity. As of December 31, 2019, the aggregate value of remaining performance obligations, excluding contracts with an original expected length of one year or less, was $7.5 million. The Company expects to recognize revenue on the remaining performance obligations over the next three years, with the majority being recognized in the next twelve months.
Share-Based Compensation	Share-Based Compensation The Company utilizes share-based compensation in the form of stock options, restricted stock units (“RSUs”) and performance-based restricted stock units (“PSUs”). The Company records compensation expense associated with share-based awards granted to employees at the fair value of the award on the date of grant. The Company uses the Black-Scholes option valuation model to determine the fair value of stock options. The fair values of RSU and PSU grants containing service or performance conditions are based on the market value of the Company’s Common Stock on the date of grant. The fair value of PSUs containing a market condition are estimated using a Monte Carlo simulation. The value of the portion of the award that is ultimately expected to vest is expensed ratably over the requisite service period as compensation expense in the consolidated statements of operations. Forfeitures are recorded as incurred. Assumptions concerning the Company’s stock price volatility and projected employee exercise behavior over the contractual life of the award impact the estimated fair value of the stock option awards.
Research and Development	Research and Development Research and development expenses include costs directly attributable to the conduct of research and development programs including personnel costs, materials and supplies associated with design work and prototype development, FDA filing fees and the cost of services provided by outside contractors such as expenses related to clinical trials. All costs associated with research and development activities are expensed as incurred.
Income Taxes	Income Taxes Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.
Net Loss Per Share	Net Loss Per Share Basic net loss per share is computed by dividing net income or loss available to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed similar to basic net loss per share except that the weighted average shares outstanding are increased to include additional shares from the assumed exercise of stock options and warrants, if dilutive. The number of additional shares is calculated by assuming that outstanding stock options or warrants were exercised and that the proceeds from such exercise were used to acquire shares of common stock at the average market price during the reporting period. All potentially dilutive common shares were excluded from the calculation because they were anti-dilutive for all annual periods presented. Potentially dilutive securities excluded from dilutive loss per share were 17,103, 17,147 and 14,761 at December 31, 2019, 2018 and 2017, respectively.
Segment Information	Segment Information Operating segments are components of an enterprise for which separate financial information is available and is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker currently evaluates the Company’s operations as a whole from a number of different operational perspectives, including but not limited to, on a product-by-product, customer and partner basis. The Company derives all significant revenues from self-administered parenteral pharmaceutical products and technologies, and has a single reportable operating segment of business.
Going Concern	Going Concern Management is responsible for evaluating, and providing disclosure of uncertainties about, the Company’s ability to continue as a going concern. As of December 31, 2019, the Company had cash, cash equivalents and investments of $45,721. Based on management’s evaluation, management concluded there is no substantial doubt or uncertainty about the Company’s ability to meet its obligations within one year from the date the consolidated financial statements were issued.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Inventories	Inventory consisted of the following: December 31, December 31, 2019 2018 Raw material $ 325 $ 26 Work in process 8,390 7,622 Finished goods 7,285 3,702 $ 16,000 $ 11,350
Components of Equipment, Molds, Furniture, and Fixtures	The Company’s equipment, molds, furniture and fixtures consisted of the following: December 31, December 31, 2019 2018 Furniture, fixtures and office equipment $ 2,480 $ 2,331 Production molds and equipment 20,749 19,678 Molds and tooling in process 1,512 456 Construction in process 989 — Less: accumulated depreciation (9,769 ) (7,570 ) $ 15,961 $ 14,895
Summary of Changes in Reserves for Product Returns and Sales Allowances	The following presents changes in reserves for product returns and sales allowances: Patient Wholesaler Prompt Rebates and Discount Distribution Payment Chargebacks Programs Returns Fees Discounts Balance at December 31, 2017 $ 1,315 $ 115 $ 245 $ 465 $ 84 Accruals and adjustments 9,586 2,429 1,628 3,519 742 Payments and other reserve reductions (8,207 ) (1,254 ) (720 ) (3,194 ) (610 ) Balance at December 31, 2018 2,694 1,290 1,153 790 216 Accruals and adjustments 15,383 6,716 2,520 6,393 1,491 Payments and other reserve reductions (11,769 ) (7,161 ) (3,303 ) (5,500 ) (1,387 ) Balance at December 31, 2019 $ 6,308 $ 845 $ 370 $ 1,683 $ 320

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2019
Leases [Abstract]
Summary of Operating Lease Maturities	The following table summarizes the Company’s operating lease maturities as of December 31, 2019: 2020 $ 1,552 2021 1,436 2022 893 2023 638 2024 650 Thereafter 4,933 Total remaining lease payments 10,102 Less: Interest (3,412 ) Total lease liabilities $ 6,690
Summary of Future Minimum Lease Payments Under Operating Leases	Under the prior leasing standard, future minimum lease payments under operating leases as of December 31, 2018 were as follows: 2019 $ 566 2020 233 2021 238 2022 60 Thereafter — Total future minimum lease payments $ 1,097

Accrued Expenses and Other Li_2

Accrued Expenses and Other Liabilities (Tables)	12 Months Ended
	Dec. 31, 2019
Payables And Accruals [Abstract]
Schedule of Accrued Expenses and Other Liabilities	Accrued expenses and other liabilities consisted of the following: December 31, December 31, 2019 2018 Accrued employee compensation and benefits $ 4,479 $ 3,715 Product returns and sales allowances 9,206 5,927 Other liabilities 2,838 2,355 $ 16,523 $ 11,997

Long-Term Debt (Tables)

Long-Term Debt (Tables)	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Schedule of Future Principal Payments under Term Loan, Including End of Term Charge	Future principal payments under the Term Loan, including the contractual End of Term Charge, are as follows: 2020 $ — 2021 16,215 2022 25,440 $ 41,655

Share Based Compensation (Table

Share Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2019
Summary of Stock Option Activity	Stock option activity under the Plan as of and for the three years ended December 31, 2019 is as follows: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Shares Price ($) Term (Years) Value ($) Outstanding at December 31, 2016 11,314 1.84 Granted/Issued 2,986 2.67 Exercised (1,311 ) 1.38 2,226 Cancelled/Forfeited (840 ) 2.68 Outstanding at December 31, 2017 12,149 2.04 Granted/Issued 2,693 2.72 Exercised (477 ) 1.14 768 Cancelled/Forfeited (286 ) 2.43 Outstanding at December 31, 2018 14,079 2.19 6.8 8,534 Granted/Issued 2,489 3.01 Exercised (2,572 ) 1.76 6,477 Cancelled/Forfeited (135 ) 2.81 Outstanding at December 31, 2019 13,861 2.41 6.7 31,713 Exercisable at December 31, 2019 10,033 2.22 5.8 24,835
Assumptions Used in Fair Value Measurement of Options Granted	December 31, 2019 2018 2017 Risk-free interest rate 1.9 % 2.8 % 1.8 % Annualized volatility 55.7 % 53.7 % 53.3 % Weighted average expected life, in years 5.5 6.0 6.0 Expected dividend yield 0.0 % 0.0 % 0.0 %
Schedule of Performance Stock Unit Awards and Restricted Stock Granted Under Long-Term Incentive Program	The performance stock unit awards and restricted stock unit awards granted under the long-term incentive program are summarized in the following table: Performance Stock Units Restricted Stock Units Number of Shares Weighted Average Date Fair Value ($) Number of Shares Weighted Average Grant Date Fair Value ($) Outstanding at December 31, 2016 1,347 1.50 823 1.39 Granted 689 3.12 689 2.69 Vested/settled — (288 ) 1.49 Forfeited/expired (581 ) 2.16 (67 ) 1.70 Outstanding at December 31, 2017 1,455 2.20 1,157 2.12 Granted 611 2.89 611 2.70 Vested/settled (173 ) 2.18 (500 ) 1.99 Forfeited/expired (51 ) 3.01 (42 ) 2.68 Outstanding at December 31, 2018 1,842 2.41 1,226 2.44 Granted 593 2.99 789 2.92 Incremental shares earned 59 1.25 — — Vested/settled (415 ) 1.18 (614 ) 2.19 Forfeited/expired (238 ) 1.12 — — Outstanding at December 31, 2019 1,841 3.00 1,401 2.82
Summary of Share Based Compensation Allocation Expense	The Company incurred compensation costs in connection with share-based awards in each of the years in the three-year period ended December 31, 2019 as follows: December 31, 2019 2018 2017 Stock options $ 3,436 $ 2,956 $ 2,378 Restricted stock units 1,830 1,173 701 Performance stock units 1,204 798 411 Total share-based compensation expense $ 6,470 $ 4,927 $ 3,490
Performance Stock Units [Member]
Assumptions Used in Fair Value Measurement of Options Granted	The fair values of the TSR PSUs granted were determined using a Monte Carlo simulation and utilized the following inputs and assumptions: 2019 Award 2018 Award 2017 Award Closing stock price on grant date $ 2.92 $ 2.70 $ 2.66 Performance period starting price $ 3.01 $ 1.92 $ 2.17 Term of award (in years) 2.55 2.57 2.57 Volatility 63.7 % 64.9 % 54.6 % Risk-free interest rate 1.79 % 2.56 % 1.39 % Expected dividend yield 0.00 % 0.00 % 0.00 % Fair value per TSR PSU $ 3.18 $ 3.27 $ 3.10

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Schedule of Income (Loss) before Income Tax Domestic and Foreign	Income (loss) before income taxes was derived from the following jurisdictions: 2019 2018 2017 U.S. $ (1,734 ) $ (6,696 ) $ (16,762 ) Switzerland (293 ) 181 19 $ (2,027 ) $ (6,515 ) $ (16,743 )
Summary of Effective Tax Rates Differ from Statutory Income Tax Rates	Effective tax rates differ from statutory income tax rates in the years ended December 31, 2019, 2018 and 2017 as follows: 2019 2018 2017 Statutory income tax rate (21.0 )% (21.0 )% (34.0 )% State income taxes (14.4 ) (3.8 ) (6.1 ) Valuation allowance increase 59.9 20.8 (102.0 ) Effect of foreign operations 1.0 (0.2 ) — Change in unused net operating loss and credit carryforwards (24.7 ) (3.9 ) 2.7 Stock-based compensation (22.3 ) (0.2 ) (3.5 ) 162(m) limitation 18.2 2.9 — Nondeductible items 1.8 3.2 (1.6 ) Impact of Tax Cuts and Jobs Act 1.5 2.2 144.5 0.0 % 0.0 % 0.0 %
Summary of Deferred Tax Assets (Liabilities)	Deferred tax assets (liabilities) as of December 31, 2019 and 2018 consist of the following: 2019 2018 Gross deferred tax assets: Net operating loss carryforward – U.S. $ 41,780 $ 42,966 Net operating loss carryforward – Switzerland 52 7 Research and development tax credit carryforward 7,559 6,891 Deferred revenue — 105 Stock-based compensation 1,999 2,324 Inventory reserve 307 440 Compensation accruals 1,154 904 Product reserves 2,329 1,302 Operating lease liabilities 1,763 — 163j interest expense limitation 475 438 Amortization 585 562 Other 61 329 Total deferred tax assets 58,064 56,268 Deferred tax liabilities: Depreciation (1,807 ) (1,511 ) Right-of-use asset, operating leases (1,648 ) — Installment obligations — (1,363 ) Total deferred tax liabilities (3,455 ) (2,874 ) Net deferred tax asset before valuation allowance 54,609 53,394 Less valuation allowance (54,609 ) (53,394 ) Net deferred tax asset $ — $ —

Revenues, Significant Custome_2

Revenues, Significant Customers and Concentrations of Risk (Tables)	12 Months Ended
	Dec. 31, 2019
Revenue From Contract With Customer [Abstract]
Summary of Revenues Disaggregated by Major Types and Sources and Customer Geographic Location	The following table presents the Company’s revenue on a disaggregated basis by major types and sources: For the Years Ended December 31, 2019 2018 2017 Proprietary product sales $ 39,215 $ 17,532 $ 17,946 Partnered product sales 52,888 30,338 23,749 Total product revenue 92,103 47,870 41,695 Licensing and development revenue 7,529 6,753 11,171 Royalties 24,232 8,931 1,649 Total revenue $ 123,864 $ 63,554 $ 54,515 Revenues disaggregated by customer geographic location are summarized as follows: For the Years Ended December 31, 2019 2018 2017 United States of America $ 120,231 $ 57,033 $ 48,924 Europe 3,463 6,157 5,061 Other 170 364 530 $ 123,864 $ 63,554 $ 54,515
Summary of Significant Customers from which the Company Derived 10% or More of Total Revenue	Significant customers from which the Company derived 10% or more of its total revenue in any of the periods presented are as follows: For the Years Ended December 31, 2019 2018 2017 Teva 41% 31% 38% AMAG 20% 29% 16% AmerisourceBergen (1) 10% 11% 11% McKesson (1) <10% 12% 16% Ferring <10% 11% 10% (1) Revenue from sales to distributors, net of estimated sales returns and allowances based on shipments.

Quarterly Financial Data (una_2

Quarterly Financial Data (unaudited) (Tables)	12 Months Ended
	Dec. 31, 2019
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Data	First Second Third Fourth 2019 Total revenues $ 23,286 $ 28,433 $ 34,306 $ 37,839 Gross profit 12,340 15,992 21,244 23,813 Net income (loss) (5,539 ) (2,226 ) 1,043 4,695 Net income (loss) per common share (1) (0.03 ) (0.01 ) 0.01 0.03 Weighted average shares, basic 160,446 162,734 163,119 163,952 Weighted average shares, diluted 160,446 162,734 168,503 171,238 2018 Total revenues $ 12,703 $ 14,162 $ 17,868 $ 18,821 Gross profit 5,517 7,202 10,579 9,191 Net income (loss) (6,193 ) (4,520 ) (1,936 ) 6,134 Net income (loss) per common share (1) (0.04 ) (0.03 ) (0.01 ) 0.04 Weighted average shares, basic 156,724 157,024 157,471 158,389 Weighted average shares, diluted 156,724 157,024 157,471 162,810 (1) Net income (loss) per common share is computed based upon the net income or loss divided by the weighted average number of shares outstanding during each period. Basic and diluted weighted average shares and income (loss) per share amounts were identical for the periods in which the Company generated net losses, as the effect of potential common shares were anti-dilutive. For the periods in which the Company generated net income, the weighted average shares on a fully diluted basis, taking into consideration the effects of dilutive stock options, restricted stock and performance stock awards for the periods in which the Company generated net income, resulted in the income per share being mathematically the same on both a basic and diluted basis.

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2019USD ($)Subsidiaryshares	Dec. 31, 2018USD ($)shares	Dec. 31, 2017USD ($)shares	Jan. 01, 2019USD ($)
Summary of Significant Accounting Policies [Line Items]
Wholly-owned subsidiaries of Antares Pharma | Subsidiary	2
Right-of-use assets	$ 5,463,000
Lease liability	6,690,000
Cash and cash equivalents, remeasured and reported at fair value	11,153,000	$ 20,569,000
Carrying value of short-term investments	22,520,000	0
Write-offs to bad debt expense	0	0	$ 0
Allowance for doubtful accounts balance	0	0
Inventory reserve	464,000	847,000
Inventory written-off	708,000	255,000
Increase in inventory reserve	325,000	592,000	356,000
Installment received in connection with the sale and transfer	5,000,000
Revenue not yet recognized recorded in contract assets	1,534,000	204,000
Depreciation expense	$ 2,205,000	2,125,000	1,536,000
Finite-lived intangible assets, amortization method	straight-line basis
Patent rights	$ 3,661,000	3,794,000
Accumulated amortization of patents	3,183,000	2,963,000
Aggregate patent amortization expense, 2020	95,000
Aggregate patent amortization expense, 2021	89,000
Aggregate patent amortization expense, 2022	83,000
Aggregate patent amortization expense, 2023	68,000
Aggregate patent amortization expense, 2024	49,000
Amortization expense	352,000	599,000	568,000
Goodwill	1,095,000	1,095,000
Goodwill impairment loss	$ 0	$ 0	$ 0
Cash discount to incentive for prompt payment	2.00%
Cash discounts offered by reducing accounts receivable	100.00%
Remaining performance obligations	$ 7,500,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Explanation	The Company expects to recognize revenue on the remaining performance obligations over the next three years, with the majority being recognized in the next twelve months
Method used for fair value assumption	Black-Scholes option valuation model
Potentially dilutive securities excluded from dilutive loss per share | shares	17,103,000	17,147,000	14,761,000
Cash, cash equivalents and investments	$ 45,721,000
Licensing and Development Revenue [Member]
Summary of Significant Accounting Policies [Line Items]
Revenue recognized	$ 1,000,000
Teva [Member]
Summary of Significant Accounting Policies [Line Items]
Future net profits from commercial sales percent	50.00%
Minimum [Member]
Summary of Significant Accounting Policies [Line Items]
Estimated useful lives	3 years
Capitalized cost being amortized over periods	5 years
Royalty payment period	45 days
Maximum [Member]
Summary of Significant Accounting Policies [Line Items]
Estimated useful lives	10 years
Capitalized cost being amortized over periods	15 years
Royalty payment period	60 days
ASU 2016-02 [Member]
Summary of Significant Accounting Policies [Line Items]
Right-of-use assets				$ 1,000,000
Lease liability				$ 1,000,000

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Inventories (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Raw material	$ 325	$ 26
Work in process	8,390	7,622
Finished goods	7,285	3,702
Inventory, Total	$ 16,000	$ 11,350

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Components of Equipment, Molds, Furniture, and Fixtures (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Property Plant And Equipment [Line Items]
Less: accumulated depreciation	$ (9,769)	$ (7,570)
Equipment, molds, furniture and fixtures, Total	15,961	14,895
Furniture, Fixtures and Office Equipment [Member]
Property Plant And Equipment [Line Items]
Equipment, molds, furniture and fixtures, gross	2,480	2,331
Production Molds and Equipment [Member]
Property Plant And Equipment [Line Items]
Equipment, molds, furniture and fixtures, gross	20,749	19,678
Molds and Tooling in Process [Member]
Property Plant And Equipment [Line Items]
Equipment, molds, furniture and fixtures, gross	1,512	$ 456
Construction in Process [Member]
Property Plant And Equipment [Line Items]
Equipment, molds, furniture and fixtures, gross	$ 989

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Summary of Changes in Reserves for Product Returns and Sales Allowances (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Rebates and Chargebacks [Member]
Revenue From Contract With Customer Contractual Adjustments [Line Items]
Balance at beginning of year	$ 2,694	$ 1,315
Accruals and adjustments	15,383	9,586
Payments and other reserve reductions	(11,769)	(8,207)
Balance at end of year	6,308	2,694
Patient Discount Programs [Member]
Revenue From Contract With Customer Contractual Adjustments [Line Items]
Balance at beginning of year	1,290	115
Accruals and adjustments	6,716	2,429
Payments and other reserve reductions	(7,161)	(1,254)
Balance at end of year	845	1,290
Returns [Member]
Revenue From Contract With Customer Contractual Adjustments [Line Items]
Balance at beginning of year	1,153	245
Accruals and adjustments	2,520	1,628
Payments and other reserve reductions	(3,303)	(720)
Balance at end of year	370	1,153
Wholesaler Distribution Fees [Member]
Revenue From Contract With Customer Contractual Adjustments [Line Items]
Balance at beginning of year	790	465
Accruals and adjustments	6,393	3,519
Payments and other reserve reductions	(5,500)	(3,194)
Balance at end of year	1,683	790
Prompt Payment Discounts [Member]
Revenue From Contract With Customer Contractual Adjustments [Line Items]
Balance at beginning of year	216	84
Accruals and adjustments	1,491	742
Payments and other reserve reductions	(1,387)	(610)
Balance at end of year	$ 320	$ 216

Summary of Significant Accoun_8

Summary of Significant Accounting Policies - Additional Information (Detail1)	Dec. 31, 2019
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2020-01-01
Summary of Significant Accounting Policies [Line Items]
Remaining performance obligation, expected to recognize, period	3 years

Leases - Additional Information

Leases - Additional Information (Detail)	Jul. 01, 2019USD ($)ft²	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Jan. 01, 2019USD ($)
Regulatory Assets [Line Items]
Right-of-use assets		$ 5,463,000
Lease liability		$ 6,690,000
Lease renewal term	3 years	2 years
Lessee, operating lease, existence of option to extend		true
Description of operating lease extension period		In May 2019, the Company amended its existing lease of the Company’s corporate headquarters to extend the lease term for an additional two years. The lease extension period commences on November 1, 2019 and expires on October 31, 2021.
Leased area | ft²	75,000
Lease term	12 years 6 months
Operating lease costs		$ 1,391,000
Cash paid for operating lease liabilities		1,401,000
Non-cash operating lease ROU assets obtained in exchange for operating lease obligations		$ 6,511,000
Weighted average discount rate		8.30%
Weighted average remaining lease term		8 years 4 months 24 days
Rent expense for operating leases			$ 695,000	$ 656,000
Maximum [Member]
Regulatory Assets [Line Items]
Operating lease, allowance	$ 1,200,000
ASU 2016-02 [Member]
Regulatory Assets [Line Items]
Right-of-use assets					$ 1,000,000
Lease liability					$ 1,000,000

Leases - Summary of Operating L

Leases - Summary of Operating Lease Maturities (Detail) $ in Thousands	Dec. 31, 2019USD ($)
Operating Lease Liabilities Payments Due [Abstract]
2020	$ 1,552
2021	1,436
2022	893
2023	638
2024	650
Thereafter	4,933
Total remaining lease payments	10,102
Less: Interest	(3,412)
Total lease liabilities	$ 6,690

Leases - Summary of Future Mini

Leases - Summary of Future Minimum Lease Payments Under Operating Leases (Detail) $ in Thousands	Dec. 31, 2018USD ($)
Operating Leases Future Minimum Payments Due [Abstract]
2019	$ 566
2020	233
2021	238
2022	60
Total future minimum lease payments	$ 1,097

Accrued Expenses and Other Li_3

Accrued Expenses and Other Liabilities - Schedule of Accrued Expenses and Other Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Payables And Accruals [Abstract]
Accrued employee compensation and benefits	$ 4,479	$ 3,715
Product returns and sales allowances	9,206	5,927
Other liabilities	2,838	2,355
Accrued expenses and other liabilities	$ 16,523	$ 11,997

Long-Term Debt - Additional Inf

Long-Term Debt - Additional Information (Detail) - USD ($)	Jun. 26, 2019	Dec. 31, 2019	Jun. 25, 2019	Dec. 31, 2018	Jun. 06, 2017
Debt Instrument [Line Items]
Carrying value of long term debt		$ 40,395,000		$ 22,083,000
Hercules Capital, Inc [Member] | Term Loan [Member]
Debt Instrument [Line Items]
Debt instrument, maturity date Description		The Term Loan is secured by substantially all of the Company’s assets, excluding intellectual property, and will mature on July 1, 2022.
Debt instrument, maturity date		Jul. 1, 2022
Debt instrument, effective interest rate		9.25%		9.50%
Debt instrument, payment terms		Payments under the Loan Agreement are interest only until the first principal payment is due, which was originally on August 1, 2019.
Debt instrument, first principal payment due date		Aug. 1, 2019
Carrying value of long term debt		$ 40,395,000		$ 25,126,000
Hercules Capital, Inc [Member] | Term Loan [Member] | First Amendment [Member]
Debt Instrument [Line Items]
Long-term debt, face amount	$ 50,000,000		$ 35,000,000
Debt instrument, payment terms		extended the interest-only payment period of the Term Loan to August 1, 2021, which may be further extended to August 1, 2022 if the Company achieves a certain loan extension milestone.
Hercules Capital, Inc [Member] | Term Loan [Member] | Prime Based Variable Rate [Member]
Debt Instrument [Line Items]
Debt Instrument, variable interest rate		9.50%
Hercules Capital, Inc [Member] | Term Loan [Member] | Maximum [Member]
Debt Instrument [Line Items]
Long-term debt, face amount					$ 35,000,000
Prepayment fee percentage on principal loan prepaid		3.00%
Hercules Capital, Inc [Member] | Term Loan [Member] | Minimum [Member]
Debt Instrument [Line Items]
Prepayment fee percentage on principal loan prepaid		1.00%
Hercules Capital, Inc [Member] | Tranche I Loan [Member]
Debt Instrument [Line Items]
Long-term debt, borrowed amount					$ 25,000,000
Percentage of loan fee on original principal amount		4.25%
Hercules Capital, Inc [Member] | Tranche II [Member]
Debt Instrument [Line Items]
Percentage of loan fee on original principal amount		3.95%
Hercules Capital, Inc [Member] | Tranche II [Member] | First Amendment [Member]
Debt Instrument [Line Items]
Long-term debt, increase in face amount	15,000,000
Hercules Capital, Inc [Member] | Tranche III [Member]
Debt Instrument [Line Items]
Percentage of loan fee on original principal amount		3.95%
Hercules Capital, Inc [Member] | Tranche III [Member] | Maximum [Member] | First Amendment [Member]
Debt Instrument [Line Items]
Debt instrument, available option to request additional advance amount	10,000,000
Hercules Capital, Inc [Member] | Tranche III [Member] | Minimum [Member] | First Amendment [Member]
Debt Instrument [Line Items]
Debt instrument, available option to request additional advance amount	$ 5,000,000

Long-Term Debt - Schedule of Fu

Long-Term Debt - Schedule of Future Principal Payments under Term Loan, Including End of Term Charge (Detail) $ in Thousands	Dec. 31, 2019USD ($)
Debt Disclosure [Abstract]
2021	$ 16,215
2022	25,440
Long-term debt	$ 41,655

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)	1 Months Ended	12 Months Ended
	Aug. 31, 2017	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Stockholders Equity [Line Items]
Aggregate offering price of common stock		$ 7,781,000	$ 7,114,000
Proceeds from sale of common stock		$ 7,781,000	$ 7,114,000	$ 0
Sales Agreement [Member] | Cowen and Company, LLC [Member]
Stockholders Equity [Line Items]
Percentage of commission on proceeds from gross sales of common stock	3.00%
Sales Agreement [Member] | Cowen and Company, LLC [Member] | Maximum [Member]
Stockholders Equity [Line Items]
Aggregate offering price of common stock	$ 30,000,000
ATM Facility [Member]
Stockholders Equity [Line Items]
Issuance of common stock, shares		2,307,000
Proceeds from sale of common stock		$ 7,781,000
Offering and Sales Agreement [Member]
Stockholders Equity [Line Items]
Issuance of common stock, shares			2,137,000
Proceeds from sale of common stock			$ 7,114,000

Share Based Compensation - Addi

Share Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from the issuance of stock options		$ 4,405	$ 474	$ 1,816
Shares withheld to meet employees' minimum statutory income tax obligation		409,000	211,000	98,000
Payments for the employees' minimum statutory income tax obligation		$ 1,131	$ 543	$ 249
Employees Tax Obligations [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Payments for the employees' minimum statutory income tax obligation		$ 1,131	$ 543	$ 249
Amended and Restated Equity Compensation Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Increase in number of shares authorized		8,000,000
Share-based compensation arrangement by share-based payment award, number of shares authorized		40,200,000
Maximum number of shares of stock granted to one participant		4,000,000
Minimum percentage of exercise price		100.00%
Shares available for grant under the plan		7,402,000
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Per share weighted average fair value of options granted		$ 1.54	$ 1.45	$ 1.37
Proceeds from the issuance of stock options		$ 4,405	$ 474	$ 1,816
Exercise of options, shares		2,529,000	447,000	1,311,000
Shares withheld to meet employees' minimum statutory income tax obligation		43,000	30,000	0
Unrecognized compensation cost related to non-vested outstanding stock awards		$ 4,780
Weighted average period expected to be recognized		1 year 10 months 24 days
Stock Options [Member] | Long Term Incentive Program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Contractual term of options granted		10 years
Vesting period		3 years
Stock Options [Member] | Amended and Restated Equity Compensation Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Contractual term of options granted		10 years
Vesting period		3 years
Stock Options [Member] | Minimum [Member] | Amended and Restated Equity Compensation Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		1 year
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares granted in 2017		789,000	611,000	689,000
Restricted Stock Units [Member] | Long Term Incentive Program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		3 years
Performance Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares granted in 2017		593,000	611,000	689,000
Performance Stock Units [Member] | Long Term Incentive Program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		3 years
Number of shares granted in 2017		662,000
Performance Stock Units [Member] | Long Term Incentive Program [Member] | Scenario, Forecast [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares approved for settlement	388,000
Performance Stock Units [Member] | Minimum [Member] | Long Term Incentive Program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation award percentage		0.00%
Performance Stock Units [Member] | Maximum [Member] | Long Term Incentive Program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation award percentage		150.00%

Share Based Compensation - Summ

Share Based Compensation - Summary of Stock Option Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Stockholders Equity Note [Abstract]
Number of Shares Outstanding, Beginning Balance	14,079,000	12,149,000	11,314,000
Number of Shares Granted/Issued	2,489,000	2,693,000	2,986,000
Number of Shares Exercised	(2,572,000)	(477,000)	(1,311,000)
Number of Shares Cancelled/Forfeited	(135,000)	(286,000)	(840,000)
Number of Shares Outstanding, Ending Balance	13,861,000	14,079,000	12,149,000
Number of Shares Exercisable, Ending Balance	10,033,000
Weighted Average Exercise Price Outstanding, Beginning Balance	$ 2.19	$ 2.04	$ 1.84
Weighted Average Exercise Price Granted/Issued	3.01	2.72	2.67
Weighted Average Exercise Price Exercised	1.76	1.14	1.38
Weighted Average Exercise Price Cancelled/Forfeited	2.81	2.43	2.68
Weighted Average Exercise Price Outstanding, Ending Balance	2.41	$ 2.19	$ 2.04
Weighted Average Exercise Price Exercisable, Ending Balance	$ 2.22
Weighted Average Remaining Contractual Term (Years) Outstanding, Ending Balance	6 years 8 months 12 days	6 years 9 months 18 days
Weighted Average Remaining Contractual Term (Years) Exercisable, Ending Balance	5 years 9 months 18 days
Aggregate Intrinsic Value, Exercised	$ 6,477	$ 768	$ 2,226
Aggregate Intrinsic Value Outstanding, Ending Balance	31,713	$ 8,534
Aggregate Intrinsic Value Exercisable, Ending Balance	$ 24,835

Share Based Compensation - Assu

Share Based Compensation - Assumptions Used in Fair Value Measurement of Options Granted (Detail)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Stockholders Equity Note [Abstract]
Risk-free interest rate	1.90%	2.80%	1.80%
Annualized volatility	55.70%	53.70%	53.30%
Weighted average expected life, in years	5 years 6 months	6 years	6 years
Expected dividend yield	0.00%	0.00%	0.00%

Share Based Compensation - Sche

Share Based Compensation - Schedule of Performance Stock Unit Awards and Restricted Stock Granted Under Long-Term Incentive Program (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Performance Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Beginning Balance	1,842,000	1,455,000	1,347,000
Number of Shares, Granted	593,000	611,000	689,000
Number of Shares, Incremental shares earned	59,000
Number of Shares, Vested/settled	(415,000)	(173,000)
Number of Shares, Forfeited/expired	(238,000)	(51,000)	(581,000)
Number of Shares, Ending Balance	1,841,000	1,842,000	1,455,000
Weighted Average Grant Date Fair Value, Beginning Balance	$ 2.41	$ 2.20	$ 1.50
Weighted Average Grant Date Fair Value, Granted	2.99	2.89	3.12
Weighted Average Grant Date Fair Value, Incremental shares earned	1.25
Weighted Average Grant Date Fair Value, Vested/settled	1.18	2.18
Weighted Average Grant Date Fair Value, Forfeited/expired	1.12	3.01	2.16
Weighted Average Grant Date Fair Value, Ending Balance	$ 3	$ 2.41	$ 2.20
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Beginning Balance	1,226,000	1,157,000	823,000
Number of Shares, Granted	789,000	611,000	689,000
Number of Shares, Vested/settled	(614,000)	(500,000)	(288,000)
Number of Shares, Forfeited/expired		(42,000)	(67,000)
Number of Shares, Ending Balance	1,401,000	1,226,000	1,157,000
Weighted Average Grant Date Fair Value, Beginning Balance	$ 2.44	$ 2.12	$ 1.39
Weighted Average Grant Date Fair Value, Granted	2.92	2.70	2.69
Weighted Average Grant Date Fair Value, Vested/settled	2.19	1.99	1.49
Weighted Average Grant Date Fair Value, Forfeited/expired		2.68	1.70
Weighted Average Grant Date Fair Value, Ending Balance	$ 2.82	$ 2.44	$ 2.12

Share Based Compensation - Fair

Share Based Compensation - Fair Value of PSUs Granted Determined Using Monte Carlo Simulation (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term of award (in years)	5 years 6 months	6 years	6 years
Volatility	55.70%	53.70%	53.30%
Risk-free interest rate	1.90%	2.80%	1.80%
Expected dividend yield	0.00%	0.00%	0.00%
Performance Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Closing stock price on grant date	$ 2.92	$ 2.70	$ 2.66
Performance period starting price	$ 3.01	$ 1.92	$ 2.17
Term of award (in years)	2 years 6 months 18 days	2 years 6 months 25 days	2 years 6 months 25 days
Volatility	63.70%	64.90%	54.60%
Risk-free interest rate	1.79%	2.56%	1.39%
Expected dividend yield	0.00%	0.00%	0.00%
Fair value per TSR PSU	$ 3.18	$ 3.27	$ 3.10

Share Based Compensation - Su_2

Share Based Compensation - Summary of Share Based Compensation Allocation Expense (Detail) - Long Term Incentive Program [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation expense	$ 6,470	$ 4,927	$ 3,490
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation expense	3,436	2,956	2,378
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation expense	1,830	1,173	701
Performance Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation expense	$ 1,204	$ 798	$ 411

Employee 401(k) Savings Plan -

Employee 401(k) Savings Plan - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Postemployment Benefits [Abstract]
Defined Contribution Plan, Plan Name	401(k)
Company plan contributions	$ 993	$ 814	$ 590

Sale of Assets - Additional Inf

Sale of Assets - Additional Information (Detail) - Asset Purchase Agreement [Member] - Ferring [Member] $ in Thousands	May 01, 2019USD ($)	Oct. 31, 2019USD ($)	Oct. 31, 2017USD ($)Installment	Dec. 31, 2019
Sale of Assets [Line Items]
Total purchase price			$ 14,500
Number of installments paid for purchase price | Installment			4
Description of purchase price payment				The purchase price was to be paid in four installments consisting of the following: a $2.0 million upfront payment, which was received upon entry into the Asset Purchase Agreement and the transfer of certain assets; a second installment of $2.75 million received upon delivery of certain documentation and satisfaction of certain conditions primarily related to product manufacturing; a third installment of $4.75 million received upon satisfaction of certain conditions, including further document transfer, the successful completion of a regulatory audit by a notified body, and a pilot manufacturing run under Ferring’s supervision; and a final installment of $5.0 million due upon Ferring’s receipt of the CE Mark needed to continue to commercialize the product in certain territories and the final transfer of certain product-related inventory, equipment and agreements to Ferring (the “Completion Date”).
Upfront payment received upon transfer of assets			$ 2,000
Consideration receivable on criteria completion related to product manufacturing			2,750
Consideration receivable on criteria completion related to Audit and pilot manufacturing			4,750
Consideration receivable on criteria completion related to Product commercialization			$ 5,000
Payment of final installment purchase price	$ 2,500
Final remaining payment received in completion date		$ 2,500

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Operating Loss Carryforwards [Line Items]
Period of incurred losses for both book and tax purposes	3 years
Valuation allowance for deferred tax assets	$ 54,609,000	$ 53,394,000
Increased total valuation allowance	1,215,000	1,356,000
Deferred tax assets, net of valuation allowances	0	0
Unrecognized tax benefits	0	0
Interest or penalties charged in relation to unrecognized tax benefits	0	0
Interest or penalties accrued in relation to unrecognized tax benefits	$ 0	$ 0
Total unrecognized tax benefits changing period	12 months
U.S Federal Tax [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carry forward	$ 166,196,000
Research credit carryforward	6,888,000
Foreign Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carry forward	$ 365,000
Tax credit carryforward expiration year	2023
Minimum [Member] | U.S Federal Tax [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforward expiration year	2020
Tax credit carryforward expiration year	2020
Maximum [Member] | U.S Federal Tax [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforward expiration year	2037
Tax credit carryforward expiration year	2039

Income Taxes - Schedule of Inco

Income Taxes - Schedule of Income (Loss) before Income Tax Domestic and Foreign (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest [Abstract]
Income (loss) before income taxes, US	$ (1,734)	$ (6,696)	$ (16,762)
Income (loss) before income taxes, Switzerland	(293)	181	19
Net loss before income taxes	$ (2,027)	$ (6,515)	$ (16,743)

Income Taxes - Summary of Effec

Income Taxes - Summary of Effective Tax Rates Differ from Statutory Income Tax Rates (Detail)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Statutory income tax rate	(21.00%)	(21.00%)	(34.00%)
State income taxes	(14.40%)	(3.80%)	(6.10%)
Valuation allowance increase	59.90%	20.80%	(102.00%)
Effect of foreign operations	1.00%	(0.20%)
Change in unused net operating loss and credit carryforwards	(24.70%)	(3.90%)	2.70%
Stock-based compensation	(22.30%)	(0.20%)	(3.50%)
162(m) limitation	18.20%	2.90%
Nondeductible items	1.80%	3.20%	(1.60%)
Impact of Tax Cuts and Jobs Act	1.50%	2.20%	144.50%
Effective income tax rate, Total	(0.00%)	(0.00%)	(0.00%)

Income Taxes - Summary of Defer

Income Taxes - Summary of Deferred Tax Assets (Liabilities) (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Gross deferred tax assets:
Net operating loss carryforward – U.S.	$ 41,780	$ 42,966
Net operating loss carryforward – Switzerland	52	7
Research and development tax credit carryforward	7,559	6,891
Deferred revenue		105
Stock-based compensation	1,999	2,324
Inventory reserve	307	440
Compensation accruals	1,154	904
Product reserves	2,329	1,302
Operating lease liabilities	1,763
163j interest expense limitation	475	438
Amortization	585	562
Other	61	329
Total deferred tax assets	58,064	56,268
Deferred tax liabilities:
Depreciation	(1,807)	(1,511)
Right-of-use asset, operating leases	(1,648)
Installment obligations		(1,363)
Total deferred tax liabilities	(3,455)	(2,874)
Net deferred tax asset before valuation allowance	54,609	53,394
Less valuation allowance	$ (54,609)	$ (53,394)

Revenues, Significant Custome_3

Revenues, Significant Customers and Concentrations of Risk - Summary of Revenue Disaggregated by Major Types and Sources (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Disaggregation Of Revenue [Line Items]
Total revenue	$ 37,839	$ 34,306	$ 28,433	$ 23,286	$ 18,821	$ 17,868	$ 14,162	$ 12,703	$ 123,864	$ 63,554	$ 54,515
Total Product Revenue [Member]
Disaggregation Of Revenue [Line Items]
Total revenue									92,103	47,870	41,695
Total Product Revenue [Member] | Proprietary Product [Member]
Disaggregation Of Revenue [Line Items]
Total revenue									39,215	17,532	17,946
Total Product Revenue [Member] | Partnered Product [Member]
Disaggregation Of Revenue [Line Items]
Total revenue									52,888	30,338	23,749
Licensing and Development Revenue [Member]
Disaggregation Of Revenue [Line Items]
Total revenue									7,529	6,753	11,171
Royalties [Member]
Disaggregation Of Revenue [Line Items]
Total revenue									$ 24,232	$ 8,931	$ 1,649

Revenues, Significant Custome_4

Revenues, Significant Customers and Concentrations of Risk - Summary of Revenues Disaggregated by Customer Geographic Location (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Disaggregation Of Revenue [Line Items]
Total revenues	$ 37,839	$ 34,306	$ 28,433	$ 23,286	$ 18,821	$ 17,868	$ 14,162	$ 12,703	$ 123,864	$ 63,554	$ 54,515
United States of America [Member]
Disaggregation Of Revenue [Line Items]
Total revenues									120,231	57,033	48,924
Europe [Member]
Disaggregation Of Revenue [Line Items]
Total revenues									3,463	6,157	5,061
Other [Member]
Disaggregation Of Revenue [Line Items]
Total revenues									$ 170	$ 364	$ 530

Revenues, Significant Custome_5

Revenues, Significant Customers and Concentrations of Risk - Summary of Significant Customers from which the Company Derived 10% or More of Total Revenue (Detail) - Customer Concentration Risk [Member]		12 Months Ended
		Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Teva [Member]
Concentration Risk [Line Items]
Total revenue by customer, percentage		41.00%	31.00%	38.00%
AMAG [Member]
Concentration Risk [Line Items]
Total revenue by customer, percentage		20.00%	29.00%	16.00%
AmerisourceBergen [Member]
Concentration Risk [Line Items]
Total revenue by customer, percentage	[1]	10.00%	11.00%	11.00%
McKesson [Member]
Concentration Risk [Line Items]
Total revenue by customer, percentage	[1]		12.00%	16.00%
McKesson [Member] | Maximum [Member]
Concentration Risk [Line Items]
Total revenue by customer, percentage	[1]	10.00%
Ferring [Member]
Concentration Risk [Line Items]
Total revenue by customer, percentage			11.00%	10.00%
Ferring [Member] | Maximum [Member]
Concentration Risk [Line Items]
Total revenue by customer, percentage		10.00%
[1]	Revenue from sales to distributors, net of estimated sales returns and allowances based on shipments.

Quarterly Financial Data (una_3

Quarterly Financial Data (unaudited) - Quarterly Financial Data (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Selected Quarterly Financial Information [Abstract]
Total revenues	$ 37,839	$ 34,306	$ 28,433	$ 23,286	$ 18,821	$ 17,868	$ 14,162	$ 12,703	$ 123,864	$ 63,554	$ 54,515
Gross profit	23,813	21,244	15,992	12,340	9,191	10,579	7,202	5,517	73,389	32,489	27,049
Net income (loss)	$ 4,695	$ 1,043	$ (2,226)	$ (5,539)	$ 6,134	$ (1,936)	$ (4,520)	$ (6,193)	$ (2,027)	$ (6,515)	$ (16,743)
Net income (loss) per common share	$ 0.03	$ 0.01	$ (0.01)	$ (0.03)	$ 0.04	$ (0.01)	$ (0.03)	$ (0.04)
Weighted average shares, basic	163,952	163,119	162,734	160,446	158,389	157,471	157,024	156,724
Weighted average shares, diluted	171,238	168,503	162,734	160,446	162,810	157,471	157,024	156,724